[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fjFldUlgh2G7E9S_cpxWOeI9g-CJOBFstg0h4Pylqeh8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":36,"phaseBuckets":37,"rows":44},"NCIC Clinical Trials Group",[4],116,false,0,40,39944,10,[13,16,19,22,24,27,30,33],{"name":14,"count":15},"Breast Cancer",19,{"name":17,"count":18},"Lung Cancer",14,{"name":20,"count":21},"Unspecified Adult Solid Tumor, Protocol Specific",13,{"name":23,"count":21},"Prostate Cancer",{"name":25,"count":26},"Lymphoma",11,{"name":28,"count":29},"Colorectal Cancer",7,{"name":31,"count":32},"Ovarian Cancer",6,{"name":34,"count":35},"Head and Neck Cancer",5,[],[38,39,40,41,42,43],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[45,180,287,360,426,491,537,601,642,672,719,749,787,817,851,878,904,930,974,1006,1032,1067,1100,1123,1145,1167,1199,1221,1255,1283,1313,1342,1364,1386,1413,1431,1456,1484,1502,1526,1553,1571,1589,1607,1625,1649,1667,1685,1703,1721,1739,1757,1775,1793,1811,1829,1852,1876,1894,1912,1942,1982,2023,2059,2092,2123,2153,2187,2219,2253,2287,2319,2350,2368,2386,2404,2428,2452,2470,2488,2512,2534,2552,2577,2595,2618,2636,2654,2677,2701,2724,2742,2764,2787,2805,2823,2848,2872,2895,2913,2937,2955,2973,2998,3016],{"intervention":46,"totalTrials":11,"cells":47},"cisplatin",{"EARLY_PHASE1":48,"PHASE1":50,"PHASE2":78,"PHASE3":113,"PHASE4":176,"NA":178},{"trials":49,"activeCount":8},[],{"trials":51,"activeCount":8},[52,63],{"nctId":53,"briefTitle":54,"status":55,"phases":56,"primaryCompletion":57,"completion":58,"start":59,"enrollment":18,"conditions":60,"interventions":61},"NCT00006036","Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors","COMPLETED",[39],"2002-09-26","2009-12-21","2000-03-22",[34,17,31,20],[46,62],"lurtotecan liposome",{"nctId":64,"briefTitle":65,"status":55,"phases":66,"primaryCompletion":67,"completion":68,"start":69,"enrollment":70,"conditions":71,"interventions":72},"NCT00343408","AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer",[39],"2007-09-18","2008-09-22","2005-11-29",31,[28,17],[73,46,74,75,76,77],"cediranib maleate","fluorouracil","gemcitabine hydrochloride","leucovorin calcium","oxaliplatin",{"trials":79,"activeCount":8},[80,91,103],{"nctId":81,"briefTitle":82,"status":55,"phases":83,"primaryCompletion":84,"completion":85,"start":86,"enrollment":87,"conditions":88,"interventions":89},"NCT00014209","Combination Chemotherapy in Hodgkin's Disease or Non-Hodgkin's Lymphoma Not Responding to Previous Treatment",[40],"2002-07-15","2009-02-10","2000-12-12",77,[25],[46,90,75],"dexamethasone",{"nctId":92,"briefTitle":93,"status":55,"phases":94,"primaryCompletion":95,"completion":96,"start":97,"enrollment":98,"conditions":99,"interventions":100},"NCT00869752","MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer",[39,40],"2012-03-15","2012-07-04","2009-12-16",12,[17],[101,46,102],"anti-IGF-1R recombinant monoclonal antibody MK-0646","etoposide",{"nctId":104,"briefTitle":105,"status":55,"phases":106,"primaryCompletion":107,"completion":85,"start":108,"enrollment":109,"conditions":110,"interventions":111},"NCT00079079","Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor",[40],"2008-09-29","2003-10-27",34,[34],[112,46,75],"carboplatin",{"trials":114,"activeCount":8},[115,126,140,152,166],{"nctId":116,"briefTitle":117,"status":55,"phases":118,"primaryCompletion":119,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":124},"NCT00820248","Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer",[41],"2015-05-16","2017-02-17","2008-12-30",320,[34],[125,46],"panitumumab",{"nctId":127,"briefTitle":128,"status":55,"phases":129,"primaryCompletion":130,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":137},"NCT00028743","Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",[41],"2008-03-05","2013-01-10","2001-08-31",819,[135,31,136],"Fallopian Tube Cancer","Peritoneal Cavity Cancer",[112,46,138,139],"paclitaxel","topotecan hydrochloride",{"nctId":141,"briefTitle":142,"status":55,"phases":143,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":149},"NCT00078949","Chemotherapy Before Autologous Stem Cell Transplantation +\u002F- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma",[41],"2013-07-29","2018-12","2003-08-27",849,[25],[150,46,151,90,75],"rituximab","cytarabine",{"nctId":153,"briefTitle":154,"status":55,"phases":155,"primaryCompletion":156,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":161},"NCT00003032","High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer",[41],"2001-04-12","2008-12-15","1997-04-25",224,[14],[162,46,163,164,165],"filgrastim","cyclophosphamide","mitoxantrone hydrochloride","tamoxifen citrate",{"nctId":167,"briefTitle":168,"status":55,"phases":169,"primaryCompletion":170,"completion":58,"start":171,"enrollment":172,"conditions":173,"interventions":174},"NCT00002583","Vinorelbine + Cisplatin or No Further Therapy in Non-small Cell Lung Cancer That Has Been Surgically Removed",[41],"2004-04-25","1994-07-07",482,[17],[46,175],"vinorelbine ditartrate",{"trials":177,"activeCount":8},[],{"trials":179,"activeCount":8},[],{"intervention":181,"totalTrials":182,"cells":183},"docetaxel",8,{"EARLY_PHASE1":184,"PHASE1":186,"PHASE2":232,"PHASE3":265,"PHASE4":283,"NA":285},{"trials":185,"activeCount":8},[],{"trials":187,"activeCount":8},[188,199,212,223],{"nctId":189,"briefTitle":190,"status":55,"phases":191,"primaryCompletion":192,"completion":58,"start":193,"enrollment":9,"conditions":194,"interventions":197},"NCT00471432","OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors",[39],"2006-03-09","2003-04-04",[195,14,196,17,31,23,20],"Bladder Cancer","Kidney Cancer",[198,181],"custirsen sodium",{"nctId":200,"briefTitle":201,"status":55,"phases":202,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":208},"NCT00372736","AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors",[39],"2009-03-24","2012-01-06","2006-07-27",27,[20],[209,181,210,211],"AEG35156","protein expression analysis","reverse transcriptase-polymerase chain reaction",{"nctId":213,"briefTitle":214,"status":55,"phases":215,"primaryCompletion":216,"completion":58,"start":217,"enrollment":218,"conditions":219,"interventions":221},"NCT00002866","Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer",[39],"2005-07-19","1996-08-12",50,[14,220],"Neutropenia",[162,181,222],"epirubicin hydrochloride",{"nctId":224,"briefTitle":225,"status":55,"phases":226,"primaryCompletion":227,"completion":228,"start":229,"enrollment":11,"conditions":230,"interventions":231},"NCT00357747","AEG35156 and Docetaxel in Treating Patients With Solid Tumors",[39],"2006-09-26","2010-06-07","2005-06-09",[20],[209,181],{"trials":233,"activeCount":8},[234,245,254],{"nctId":235,"briefTitle":236,"status":55,"phases":237,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":243},"NCT00066443","Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer",[39,40],"2010-01-06","2014-01-16","2003-11-03",93,[14],[244,181,222],"pegfilgrastim",{"nctId":246,"briefTitle":247,"status":55,"phases":248,"primaryCompletion":249,"completion":68,"start":250,"enrollment":251,"conditions":252,"interventions":253},"NCT00258375","OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer",[40],"2007-02-23","2005-10-21",15,[14],[198,181],{"nctId":255,"briefTitle":256,"status":55,"phases":257,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":262,"interventions":263},"NCT00258388","Docetaxel and Prednisone With\u002FOut OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy",[40],"2007-11-08","2011-01-18","2005-09-28",82,[23],[198,181,264],"prednisone",{"trials":266,"activeCount":8},[267],{"nctId":268,"briefTitle":269,"status":270,"phases":271,"primaryCompletion":272,"completion":259,"start":273,"enrollment":274,"conditions":275,"interventions":276},"NCT00651326","Androgen Suppression and Radiation With\u002FOut Docetaxel in High-Risk Localized Prostate Cancer","TERMINATED",[41],"2010-05-14","2008-06-02",48,[23],[277,278,279,280,281,282],"bicalutamide","buserelin","flutamide","goserelin","leuprolide acetate","Docetaxel",{"trials":284,"activeCount":8},[],{"trials":286,"activeCount":8},[],{"intervention":75,"totalTrials":182,"cells":288},{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":297,"PHASE3":328,"PHASE4":356,"NA":358},{"trials":290,"activeCount":8},[],{"trials":292,"activeCount":8},[293],{"nctId":64,"briefTitle":65,"status":55,"phases":294,"primaryCompletion":67,"completion":68,"start":69,"enrollment":70,"conditions":295,"interventions":296},[39],[28,17],[73,46,74,75,76,77],{"trials":298,"activeCount":8},[299,303,314,324],{"nctId":81,"briefTitle":82,"status":55,"phases":300,"primaryCompletion":84,"completion":85,"start":86,"enrollment":87,"conditions":301,"interventions":302},[40],[25],[46,90,75],{"nctId":304,"briefTitle":305,"status":55,"phases":306,"primaryCompletion":307,"completion":308,"start":309,"enrollment":310,"conditions":311,"interventions":312},"NCT00377052","Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma",[40],"2009-04-21","2011-06-21","2007-01-16",29,[25],[313,75],"bortezomib",{"nctId":315,"briefTitle":316,"status":55,"phases":317,"primaryCompletion":318,"completion":204,"start":319,"enrollment":109,"conditions":320,"interventions":322},"NCT00265876","AZD0530 and Gemcitabine in Locally Advanced\u002FMetastatic Pancreatic Cancer That Cannot Be Removed By Surgery",[39,40],"2009-01-08","2006-04-26",[321],"Pancreatic Cancer",[323,75],"AZD0530",{"nctId":104,"briefTitle":105,"status":55,"phases":325,"primaryCompletion":107,"completion":85,"start":108,"enrollment":109,"conditions":326,"interventions":327},[40],[34],[112,46,75],{"trials":329,"activeCount":8},[330,340,352],{"nctId":331,"briefTitle":332,"status":55,"phases":333,"primaryCompletion":334,"completion":85,"start":335,"enrollment":336,"conditions":337,"interventions":338},"NCT00026338","Gemcitabine With\u002FOut Erlotinib in Unresectable Locally Advanced\u002FMetastatic Pancreatic Cancer",[41],"2004-09-17","2001-10-29",569,[321],[339,75],"erlotinib hydrochloride",{"nctId":341,"briefTitle":342,"status":270,"phases":343,"primaryCompletion":344,"completion":259,"start":345,"enrollment":15,"conditions":346,"interventions":350},"NCT00658593","Gemcitabine With\u002FOut Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer",[41],"2010-05-11","2008-10-10",[347,348,349],"Extrahepatic Bile Duct Cancer","Gallbladder Cancer","Liver Cancer",[351,75],"capecitabine",{"nctId":141,"briefTitle":142,"status":55,"phases":353,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":354,"interventions":355},[41],[25],[150,46,151,90,75],{"trials":357,"activeCount":8},[],{"trials":359,"activeCount":8},[],{"intervention":112,"totalTrials":29,"cells":361},{"EARLY_PHASE1":362,"PHASE1":364,"PHASE2":374,"PHASE3":388,"PHASE4":422,"NA":424},{"trials":363,"activeCount":8},[],{"trials":365,"activeCount":8},[366],{"nctId":367,"briefTitle":368,"status":55,"phases":369,"primaryCompletion":370,"completion":259,"start":371,"enrollment":218,"conditions":372,"interventions":373},"NCT00107250","AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8\u002F9\u002F07)",[39],"2009-10-23","2005-01-21",[28,17,20],[351,112,73,138],{"trials":375,"activeCount":8},[376,384],{"nctId":377,"briefTitle":378,"status":55,"phases":379,"primaryCompletion":380,"completion":58,"start":381,"enrollment":218,"conditions":382,"interventions":383},"NCT00030446","Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[40],"2005-02-11","2002-01-10",[135,31,136],[112,339],{"nctId":104,"briefTitle":105,"status":55,"phases":385,"primaryCompletion":107,"completion":85,"start":108,"enrollment":109,"conditions":386,"interventions":387},[40],[34],[112,46,75],{"trials":389,"activeCount":8},[390,400,404,413],{"nctId":391,"briefTitle":392,"status":55,"phases":393,"primaryCompletion":394,"completion":85,"start":395,"enrollment":396,"conditions":397,"interventions":398},"NCT00006229","Paclitaxel + Carboplatin With\u002Fut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer",[40,41],"2003-12-10","2000-04-04",774,[17],[112,138,399],"rebimastat",{"nctId":127,"briefTitle":128,"status":55,"phases":401,"primaryCompletion":130,"completion":131,"start":132,"enrollment":133,"conditions":402,"interventions":403},[41],[135,31,136],[112,46,138,139],{"nctId":405,"briefTitle":406,"status":55,"phases":407,"primaryCompletion":408,"completion":239,"start":409,"enrollment":410,"conditions":411,"interventions":412},"NCT00795340","Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[41],"2012-01-09","2009-02-04",306,[17],[112,73,138],{"nctId":414,"briefTitle":415,"status":55,"phases":416,"primaryCompletion":417,"completion":131,"start":418,"enrollment":419,"conditions":420,"interventions":421},"NCT00245154","Paclitaxel + Carboplatin With\u002FOut Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer",[40,41],"2008-07-04","2005-11-03",296,[17],[112,73,138],{"trials":423,"activeCount":8},[],{"trials":425,"activeCount":8},[],{"intervention":90,"totalTrials":32,"cells":427},{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":432,"PHASE3":449,"PHASE4":487,"NA":489},{"trials":429,"activeCount":8},[],{"trials":431,"activeCount":8},[],{"trials":433,"activeCount":8},[434,445],{"nctId":435,"briefTitle":436,"status":55,"phases":437,"primaryCompletion":438,"completion":438,"start":192,"enrollment":439,"conditions":440,"interventions":442},"NCT00305812","Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma",[40],"2008-06-30",51,[441],"Multiple Myeloma and Plasma Cell Neoplasm",[90,443,444],"lenalidomide","melphalan",{"nctId":81,"briefTitle":82,"status":55,"phases":446,"primaryCompletion":84,"completion":85,"start":86,"enrollment":87,"conditions":447,"interventions":448},[40],[25],[46,90,75],{"trials":450,"activeCount":8},[451,463,467,478],{"nctId":452,"briefTitle":453,"status":55,"phases":454,"primaryCompletion":455,"completion":456,"start":457,"enrollment":458,"conditions":459,"interventions":461},"NCT01248585","Dexamethasone vs Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases",[41],"2015-05-25","2015-11-27","2011-05-30",298,[460],"Bone Metastases",[462],"Dexamethasone",{"nctId":141,"briefTitle":142,"status":55,"phases":464,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":465,"interventions":466},[41],[25],[150,46,151,90,75],{"nctId":468,"briefTitle":469,"status":55,"phases":470,"primaryCompletion":471,"completion":85,"start":472,"enrollment":473,"conditions":474,"interventions":476},"NCT00016380","Ondansetron With\u002FOut Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen",[41],"2004-04-30","2001-02-28",211,[475],"Cancer",[90,477],"ondansetron",{"nctId":479,"briefTitle":480,"status":55,"phases":481,"primaryCompletion":482,"completion":58,"start":483,"enrollment":484,"conditions":485,"interventions":486},"NCT00002678","Combination Chemotherapy in Treating Patients With Multiple Myeloma",[41],"2004-05-03","1995-06-02",595,[441],[90,444,264],{"trials":488,"activeCount":8},[],{"trials":490,"activeCount":8},[],{"intervention":138,"totalTrials":32,"cells":492},{"EARLY_PHASE1":493,"PHASE1":495,"PHASE2":501,"PHASE3":503,"PHASE4":533,"NA":535},{"trials":494,"activeCount":8},[],{"trials":496,"activeCount":8},[497],{"nctId":367,"briefTitle":368,"status":55,"phases":498,"primaryCompletion":370,"completion":259,"start":371,"enrollment":218,"conditions":499,"interventions":500},[39],[28,17,20],[351,112,73,138],{"trials":502,"activeCount":8},[],{"trials":504,"activeCount":8},[505,509,513,517,529],{"nctId":391,"briefTitle":392,"status":55,"phases":506,"primaryCompletion":394,"completion":85,"start":395,"enrollment":396,"conditions":507,"interventions":508},[40,41],[17],[112,138,399],{"nctId":127,"briefTitle":128,"status":55,"phases":510,"primaryCompletion":130,"completion":131,"start":132,"enrollment":133,"conditions":511,"interventions":512},[41],[135,31,136],[112,46,138,139],{"nctId":405,"briefTitle":406,"status":55,"phases":514,"primaryCompletion":408,"completion":239,"start":409,"enrollment":410,"conditions":515,"interventions":516},[41],[17],[112,73,138],{"nctId":518,"briefTitle":519,"status":55,"phases":520,"primaryCompletion":521,"completion":522,"start":523,"enrollment":524,"conditions":525,"interventions":526},"NCT00014222","Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer",[41],"2014-02-10","2014-03-17","2000-12-04",2104,[14],[527,162,163,528,222,74,138],"epoetin alfa","doxorubicin hydrochloride",{"nctId":414,"briefTitle":415,"status":55,"phases":530,"primaryCompletion":417,"completion":131,"start":418,"enrollment":419,"conditions":531,"interventions":532},[40,41],[17],[112,73,138],{"trials":534,"activeCount":8},[],{"trials":536,"activeCount":8},[],{"intervention":264,"totalTrials":32,"cells":538},{"EARLY_PHASE1":539,"PHASE1":541,"PHASE2":543,"PHASE3":569,"PHASE4":597,"NA":599},{"trials":540,"activeCount":8},[],{"trials":542,"activeCount":8},[],{"trials":544,"activeCount":8},[545,555,559],{"nctId":546,"briefTitle":547,"status":55,"phases":548,"primaryCompletion":549,"completion":157,"start":550,"enrollment":551,"conditions":552,"interventions":553},"NCT00006890","Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma",[40],"2002-05-03","2000-07-12",67,[441],[264,554],"thalidomide",{"nctId":255,"briefTitle":256,"status":55,"phases":556,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":557,"interventions":558},[40],[23],[198,181,264],{"nctId":560,"briefTitle":561,"status":55,"phases":562,"primaryCompletion":563,"completion":204,"start":564,"enrollment":565,"conditions":566,"interventions":567},"NCT00428142","Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma",[40],"2011-04","2007-05-01",95,[25],[150,313,163,264,568],"vincristine sulfate",{"trials":570,"activeCount":8},[571,581,585],{"nctId":572,"briefTitle":573,"status":55,"phases":574,"primaryCompletion":575,"completion":576,"start":577,"enrollment":578,"conditions":579,"interventions":580},"NCT00049673","Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma",[41],"2011-10-19","2013-09-19","2002-10-15",332,[441],[264,554],{"nctId":479,"briefTitle":480,"status":55,"phases":582,"primaryCompletion":482,"completion":58,"start":483,"enrollment":484,"conditions":583,"interventions":584},[41],[441],[90,444,264],{"nctId":586,"briefTitle":587,"status":55,"phases":588,"primaryCompletion":589,"completion":85,"start":590,"enrollment":591,"conditions":592,"interventions":595},"NCT00003232","Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer",[41],"2002-05-01","1997-11-24",227,[593,23,594],"Pain","Quality of Life",[596,164,264],"clodronate disodium",{"trials":598,"activeCount":8},[],{"trials":600,"activeCount":8},[],{"intervention":339,"totalTrials":602,"cells":603},4,{"EARLY_PHASE1":604,"PHASE1":606,"PHASE2":616,"PHASE3":632,"PHASE4":638,"NA":640},{"trials":605,"activeCount":8},[],{"trials":607,"activeCount":8},[608],{"nctId":609,"briefTitle":610,"status":55,"phases":611,"primaryCompletion":612,"completion":259,"start":613,"enrollment":15,"conditions":614,"interventions":615},"NCT00079053","Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck",[39],"2008-12-09","2004-03-02",[34],[339],{"trials":617,"activeCount":8},[618,628],{"nctId":619,"briefTitle":620,"status":55,"phases":621,"primaryCompletion":622,"completion":623,"start":624,"enrollment":70,"conditions":625,"interventions":626},"NCT01068587","MET\u002FVEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy",[39,40],"2014-03-21","2015-02-13","2010-01-21",[17],[627,339],"MET\u002FVEGFR2 inhibitor Foretinib",{"nctId":377,"briefTitle":378,"status":55,"phases":629,"primaryCompletion":380,"completion":58,"start":381,"enrollment":218,"conditions":630,"interventions":631},[40],[135,31,136],[112,339],{"trials":633,"activeCount":8},[634],{"nctId":331,"briefTitle":332,"status":55,"phases":635,"primaryCompletion":334,"completion":85,"start":335,"enrollment":336,"conditions":636,"interventions":637},[41],[321],[339,75],{"trials":639,"activeCount":8},[],{"trials":641,"activeCount":8},[],{"intervention":73,"totalTrials":602,"cells":643},{"EARLY_PHASE1":644,"PHASE1":646,"PHASE2":656,"PHASE3":658,"PHASE4":668,"NA":670},{"trials":645,"activeCount":8},[],{"trials":647,"activeCount":8},[648,652],{"nctId":367,"briefTitle":368,"status":55,"phases":649,"primaryCompletion":370,"completion":259,"start":371,"enrollment":218,"conditions":650,"interventions":651},[39],[28,17,20],[351,112,73,138],{"nctId":64,"briefTitle":65,"status":55,"phases":653,"primaryCompletion":67,"completion":68,"start":69,"enrollment":70,"conditions":654,"interventions":655},[39],[28,17],[73,46,74,75,76,77],{"trials":657,"activeCount":8},[],{"trials":659,"activeCount":8},[660,664],{"nctId":405,"briefTitle":406,"status":55,"phases":661,"primaryCompletion":408,"completion":239,"start":409,"enrollment":410,"conditions":662,"interventions":663},[41],[17],[112,73,138],{"nctId":414,"briefTitle":415,"status":55,"phases":665,"primaryCompletion":417,"completion":131,"start":418,"enrollment":419,"conditions":666,"interventions":667},[40,41],[17],[112,73,138],{"trials":669,"activeCount":8},[],{"trials":671,"activeCount":8},[],{"intervention":278,"totalTrials":602,"cells":673},{"EARLY_PHASE1":674,"PHASE1":676,"PHASE2":687,"PHASE3":689,"PHASE4":715,"NA":717},{"trials":675,"activeCount":8},[],{"trials":677,"activeCount":8},[678],{"nctId":679,"briefTitle":680,"status":55,"phases":681,"primaryCompletion":682,"completion":68,"start":683,"enrollment":684,"conditions":685,"interventions":686},"NCT00054106","Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer",[39],"2004-09-23","2002-12-10",25,[23],[278,198,279],{"trials":688,"activeCount":8},[],{"trials":690,"activeCount":8},[691,701,705],{"nctId":692,"briefTitle":693,"status":55,"phases":694,"primaryCompletion":695,"completion":204,"start":696,"enrollment":697,"conditions":698,"interventions":699},"NCT00002633","Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer",[41],"2011-09-23","1995-02-08",361,[23],[277,278,279,280,281,700],"nilutamide",{"nctId":268,"briefTitle":269,"status":270,"phases":702,"primaryCompletion":272,"completion":259,"start":273,"enrollment":274,"conditions":703,"interventions":704},[41],[23],[277,278,279,280,281,282],{"nctId":706,"briefTitle":707,"status":55,"phases":708,"primaryCompletion":709,"completion":131,"start":710,"enrollment":711,"conditions":712,"interventions":713},"NCT00003653","Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer",[41],"2010-10-04","1999-01-05",1386,[23],[277,278,714,279,280,281,700],"cyproterone acetate",{"trials":716,"activeCount":8},[],{"trials":718,"activeCount":8},[],{"intervention":279,"totalTrials":602,"cells":720},{"EARLY_PHASE1":721,"PHASE1":723,"PHASE2":729,"PHASE3":731,"PHASE4":745,"NA":747},{"trials":722,"activeCount":8},[],{"trials":724,"activeCount":8},[725],{"nctId":679,"briefTitle":680,"status":55,"phases":726,"primaryCompletion":682,"completion":68,"start":683,"enrollment":684,"conditions":727,"interventions":728},[39],[23],[278,198,279],{"trials":730,"activeCount":8},[],{"trials":732,"activeCount":8},[733,737,741],{"nctId":692,"briefTitle":693,"status":55,"phases":734,"primaryCompletion":695,"completion":204,"start":696,"enrollment":697,"conditions":735,"interventions":736},[41],[23],[277,278,279,280,281,700],{"nctId":268,"briefTitle":269,"status":270,"phases":738,"primaryCompletion":272,"completion":259,"start":273,"enrollment":274,"conditions":739,"interventions":740},[41],[23],[277,278,279,280,281,282],{"nctId":706,"briefTitle":707,"status":55,"phases":742,"primaryCompletion":709,"completion":131,"start":710,"enrollment":711,"conditions":743,"interventions":744},[41],[23],[277,278,714,279,280,281,700],{"trials":746,"activeCount":8},[],{"trials":748,"activeCount":8},[],{"intervention":222,"totalTrials":602,"cells":750},{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":759,"PHASE3":765,"PHASE4":783,"NA":785},{"trials":752,"activeCount":8},[],{"trials":754,"activeCount":8},[755],{"nctId":213,"briefTitle":214,"status":55,"phases":756,"primaryCompletion":216,"completion":58,"start":217,"enrollment":218,"conditions":757,"interventions":758},[39],[14,220],[162,181,222],{"trials":760,"activeCount":8},[761],{"nctId":235,"briefTitle":236,"status":55,"phases":762,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":763,"interventions":764},[39,40],[14],[244,181,222],{"trials":766,"activeCount":8},[767,779],{"nctId":768,"briefTitle":769,"status":55,"phases":770,"primaryCompletion":771,"completion":772,"start":773,"enrollment":774,"conditions":775,"interventions":776},"NCT00002542","Tamoxifen in Treating Women With High-Risk Breast Cancer",[41],"2007-03-07","2011-01-11","1993-07-20",672,[14],[777,163,528,222,74,778,165],"CMF regimen","methotrexate",{"nctId":518,"briefTitle":519,"status":55,"phases":780,"primaryCompletion":521,"completion":522,"start":523,"enrollment":524,"conditions":781,"interventions":782},[41],[14],[527,162,163,528,222,74,138],{"trials":784,"activeCount":8},[],{"trials":786,"activeCount":8},[],{"intervention":163,"totalTrials":602,"cells":788},{"EARLY_PHASE1":789,"PHASE1":791,"PHASE2":793,"PHASE3":799,"PHASE4":813,"NA":815},{"trials":790,"activeCount":8},[],{"trials":792,"activeCount":8},[],{"trials":794,"activeCount":8},[795],{"nctId":560,"briefTitle":561,"status":55,"phases":796,"primaryCompletion":563,"completion":204,"start":564,"enrollment":565,"conditions":797,"interventions":798},[40],[25],[150,313,163,264,568],{"trials":800,"activeCount":8},[801,805,809],{"nctId":768,"briefTitle":769,"status":55,"phases":802,"primaryCompletion":771,"completion":772,"start":773,"enrollment":774,"conditions":803,"interventions":804},[41],[14],[777,163,528,222,74,778,165],{"nctId":153,"briefTitle":154,"status":55,"phases":806,"primaryCompletion":156,"completion":157,"start":158,"enrollment":159,"conditions":807,"interventions":808},[41],[14],[162,46,163,164,165],{"nctId":518,"briefTitle":519,"status":55,"phases":810,"primaryCompletion":521,"completion":522,"start":523,"enrollment":524,"conditions":811,"interventions":812},[41],[14],[527,162,163,528,222,74,138],{"trials":814,"activeCount":8},[],{"trials":816,"activeCount":8},[],{"intervention":74,"totalTrials":602,"cells":818},{"EARLY_PHASE1":819,"PHASE1":821,"PHASE2":827,"PHASE3":829,"PHASE4":847,"NA":849},{"trials":820,"activeCount":8},[],{"trials":822,"activeCount":8},[823],{"nctId":64,"briefTitle":65,"status":55,"phases":824,"primaryCompletion":67,"completion":68,"start":69,"enrollment":70,"conditions":825,"interventions":826},[39],[28,17],[73,46,74,75,76,77],{"trials":828,"activeCount":8},[],{"trials":830,"activeCount":8},[831,835,843],{"nctId":768,"briefTitle":769,"status":55,"phases":832,"primaryCompletion":771,"completion":772,"start":773,"enrollment":774,"conditions":833,"interventions":834},[41],[14],[777,163,528,222,74,778,165],{"nctId":836,"briefTitle":837,"status":55,"phases":838,"primaryCompletion":839,"completion":85,"start":840,"enrollment":551,"conditions":841,"interventions":842},"NCT00002570","Immediate Compared With Delayed Chemotherapy in Advanced Colorectal Cancer Without Signs or Symptoms of Disease",[41],"2000-11","1994-07-15",[28],[74,76],{"nctId":518,"briefTitle":519,"status":55,"phases":844,"primaryCompletion":521,"completion":522,"start":523,"enrollment":524,"conditions":845,"interventions":846},[41],[14],[527,162,163,528,222,74,138],{"trials":848,"activeCount":8},[],{"trials":850,"activeCount":8},[],{"intervention":277,"totalTrials":852,"cells":853},3,{"EARLY_PHASE1":854,"PHASE1":856,"PHASE2":858,"PHASE3":860,"PHASE4":874,"NA":876},{"trials":855,"activeCount":8},[],{"trials":857,"activeCount":8},[],{"trials":859,"activeCount":8},[],{"trials":861,"activeCount":8},[862,866,870],{"nctId":692,"briefTitle":693,"status":55,"phases":863,"primaryCompletion":695,"completion":204,"start":696,"enrollment":697,"conditions":864,"interventions":865},[41],[23],[277,278,279,280,281,700],{"nctId":268,"briefTitle":269,"status":270,"phases":867,"primaryCompletion":272,"completion":259,"start":273,"enrollment":274,"conditions":868,"interventions":869},[41],[23],[277,278,279,280,281,282],{"nctId":706,"briefTitle":707,"status":55,"phases":871,"primaryCompletion":709,"completion":131,"start":710,"enrollment":711,"conditions":872,"interventions":873},[41],[23],[277,278,714,279,280,281,700],{"trials":875,"activeCount":8},[],{"trials":877,"activeCount":8},[],{"intervention":280,"totalTrials":852,"cells":879},{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":886,"PHASE4":900,"NA":902},{"trials":881,"activeCount":8},[],{"trials":883,"activeCount":8},[],{"trials":885,"activeCount":8},[],{"trials":887,"activeCount":8},[888,892,896],{"nctId":692,"briefTitle":693,"status":55,"phases":889,"primaryCompletion":695,"completion":204,"start":696,"enrollment":697,"conditions":890,"interventions":891},[41],[23],[277,278,279,280,281,700],{"nctId":268,"briefTitle":269,"status":270,"phases":893,"primaryCompletion":272,"completion":259,"start":273,"enrollment":274,"conditions":894,"interventions":895},[41],[23],[277,278,279,280,281,282],{"nctId":706,"briefTitle":707,"status":55,"phases":897,"primaryCompletion":709,"completion":131,"start":710,"enrollment":711,"conditions":898,"interventions":899},[41],[23],[277,278,714,279,280,281,700],{"trials":901,"activeCount":8},[],{"trials":903,"activeCount":8},[],{"intervention":281,"totalTrials":852,"cells":905},{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":912,"PHASE4":926,"NA":928},{"trials":907,"activeCount":8},[],{"trials":909,"activeCount":8},[],{"trials":911,"activeCount":8},[],{"trials":913,"activeCount":8},[914,918,922],{"nctId":692,"briefTitle":693,"status":55,"phases":915,"primaryCompletion":695,"completion":204,"start":696,"enrollment":697,"conditions":916,"interventions":917},[41],[23],[277,278,279,280,281,700],{"nctId":268,"briefTitle":269,"status":270,"phases":919,"primaryCompletion":272,"completion":259,"start":273,"enrollment":274,"conditions":920,"interventions":921},[41],[23],[277,278,279,280,281,282],{"nctId":706,"briefTitle":707,"status":55,"phases":923,"primaryCompletion":709,"completion":131,"start":710,"enrollment":711,"conditions":924,"interventions":925},[41],[23],[277,278,714,279,280,281,700],{"trials":927,"activeCount":8},[],{"trials":929,"activeCount":8},[],{"intervention":931,"totalTrials":852,"cells":932},"letrozole",{"EARLY_PHASE1":933,"PHASE1":935,"PHASE2":937,"PHASE3":958,"PHASE4":970,"NA":972},{"trials":934,"activeCount":8},[],{"trials":936,"activeCount":8},[],{"trials":938,"activeCount":8},[939,948],{"nctId":940,"briefTitle":941,"status":55,"phases":942,"primaryCompletion":943,"completion":85,"start":944,"enrollment":945,"conditions":946,"interventions":947},"NCT00238316","Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density",[40],"2007-11-16","2000-12-05",68,[14],[931],{"nctId":949,"briefTitle":950,"status":55,"phases":951,"primaryCompletion":952,"completion":259,"start":953,"enrollment":954,"conditions":955,"interventions":957},"NCT00004251","Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer",[40],"2002-09-13","2000-01-19",33,[956],"Endometrial Cancer",[931],{"trials":959,"activeCount":8},[960],{"nctId":961,"briefTitle":962,"status":55,"phases":963,"primaryCompletion":964,"completion":965,"start":966,"enrollment":967,"conditions":968,"interventions":969},"NCT00003140","Letrozole After Tamoxifen in Treating Women With Breast Cancer",[41],"2003-08-22","2003-10","1998-08-24",5187,[14],[931],{"trials":971,"activeCount":8},[],{"trials":973,"activeCount":8},[],{"intervention":150,"totalTrials":852,"cells":975},{"EARLY_PHASE1":976,"PHASE1":978,"PHASE2":980,"PHASE3":986,"PHASE4":1002,"NA":1004},{"trials":977,"activeCount":8},[],{"trials":979,"activeCount":8},[],{"trials":981,"activeCount":8},[982],{"nctId":560,"briefTitle":561,"status":55,"phases":983,"primaryCompletion":563,"completion":204,"start":564,"enrollment":565,"conditions":984,"interventions":985},[40],[25],[150,313,163,264,568],{"trials":987,"activeCount":8},[988,998],{"nctId":989,"briefTitle":990,"status":55,"phases":991,"primaryCompletion":992,"completion":239,"start":993,"enrollment":994,"conditions":995,"interventions":996},"NCT00064116","Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma",[41],"2010-12","2001-05-08",824,[25],[150,997],"CHOP regimen",{"nctId":141,"briefTitle":142,"status":55,"phases":999,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":1000,"interventions":1001},[41],[25],[150,46,151,90,75],{"trials":1003,"activeCount":8},[],{"trials":1005,"activeCount":8},[],{"intervention":162,"totalTrials":852,"cells":1007},{"EARLY_PHASE1":1008,"PHASE1":1010,"PHASE2":1016,"PHASE3":1018,"PHASE4":1028,"NA":1030},{"trials":1009,"activeCount":8},[],{"trials":1011,"activeCount":8},[1012],{"nctId":213,"briefTitle":214,"status":55,"phases":1013,"primaryCompletion":216,"completion":58,"start":217,"enrollment":218,"conditions":1014,"interventions":1015},[39],[14,220],[162,181,222],{"trials":1017,"activeCount":8},[],{"trials":1019,"activeCount":8},[1020,1024],{"nctId":153,"briefTitle":154,"status":55,"phases":1021,"primaryCompletion":156,"completion":157,"start":158,"enrollment":159,"conditions":1022,"interventions":1023},[41],[14],[162,46,163,164,165],{"nctId":518,"briefTitle":519,"status":55,"phases":1025,"primaryCompletion":521,"completion":522,"start":523,"enrollment":524,"conditions":1026,"interventions":1027},[41],[14],[527,162,163,528,222,74,138],{"trials":1029,"activeCount":8},[],{"trials":1031,"activeCount":8},[],{"intervention":528,"totalTrials":852,"cells":1033},{"EARLY_PHASE1":1034,"PHASE1":1036,"PHASE2":1038,"PHASE3":1040,"PHASE4":1063,"NA":1065},{"trials":1035,"activeCount":8},[],{"trials":1037,"activeCount":8},[],{"trials":1039,"activeCount":8},[],{"trials":1041,"activeCount":8},[1042,1046,1059],{"nctId":768,"briefTitle":769,"status":55,"phases":1043,"primaryCompletion":771,"completion":772,"start":773,"enrollment":774,"conditions":1044,"interventions":1045},[41],[14],[777,163,528,222,74,778,165],{"nctId":1047,"briefTitle":1048,"status":55,"phases":1049,"primaryCompletion":1050,"completion":204,"start":1051,"enrollment":1052,"conditions":1053,"interventions":1055},"NCT00002561","Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease",[41],"2011-08-15","1994-01-25",405,[1054],"Hodgkin Lymphoma",[1056,1057,528,1058],"bleomycin sulfate","dacarbazine","vinblastine",{"nctId":518,"briefTitle":519,"status":55,"phases":1060,"primaryCompletion":521,"completion":522,"start":523,"enrollment":524,"conditions":1061,"interventions":1062},[41],[14],[527,162,163,528,222,74,138],{"trials":1064,"activeCount":8},[],{"trials":1066,"activeCount":8},[],{"intervention":165,"totalTrials":852,"cells":1068},{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1073,"PHASE3":1075,"PHASE4":1096,"NA":1098},{"trials":1070,"activeCount":8},[],{"trials":1072,"activeCount":8},[],{"trials":1074,"activeCount":8},[],{"trials":1076,"activeCount":8},[1077,1081,1085],{"nctId":768,"briefTitle":769,"status":55,"phases":1078,"primaryCompletion":771,"completion":772,"start":773,"enrollment":774,"conditions":1079,"interventions":1080},[41],[14],[777,163,528,222,74,778,165],{"nctId":153,"briefTitle":154,"status":55,"phases":1082,"primaryCompletion":156,"completion":157,"start":158,"enrollment":159,"conditions":1083,"interventions":1084},[41],[14],[162,46,163,164,165],{"nctId":1086,"briefTitle":1087,"status":55,"phases":1088,"primaryCompletion":1089,"completion":1090,"start":1091,"enrollment":1092,"conditions":1093,"interventions":1094},"NCT00002864","Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer",[41],"2007-12-07","2010-04-23","1996-09-24",667,[14],[1095,165],"octreotide acetate",{"trials":1097,"activeCount":8},[],{"trials":1099,"activeCount":8},[],{"intervention":351,"totalTrials":1101,"cells":1102},2,{"EARLY_PHASE1":1103,"PHASE1":1105,"PHASE2":1111,"PHASE3":1113,"PHASE4":1119,"NA":1121},{"trials":1104,"activeCount":8},[],{"trials":1106,"activeCount":8},[1107],{"nctId":367,"briefTitle":368,"status":55,"phases":1108,"primaryCompletion":370,"completion":259,"start":371,"enrollment":218,"conditions":1109,"interventions":1110},[39],[28,17,20],[351,112,73,138],{"trials":1112,"activeCount":8},[],{"trials":1114,"activeCount":8},[1115],{"nctId":341,"briefTitle":342,"status":270,"phases":1116,"primaryCompletion":344,"completion":259,"start":345,"enrollment":15,"conditions":1117,"interventions":1118},[41],[347,348,349],[351,75],{"trials":1120,"activeCount":8},[],{"trials":1122,"activeCount":8},[],{"intervention":700,"totalTrials":1101,"cells":1124},{"EARLY_PHASE1":1125,"PHASE1":1127,"PHASE2":1129,"PHASE3":1131,"PHASE4":1141,"NA":1143},{"trials":1126,"activeCount":8},[],{"trials":1128,"activeCount":8},[],{"trials":1130,"activeCount":8},[],{"trials":1132,"activeCount":8},[1133,1137],{"nctId":692,"briefTitle":693,"status":55,"phases":1134,"primaryCompletion":695,"completion":204,"start":696,"enrollment":697,"conditions":1135,"interventions":1136},[41],[23],[277,278,279,280,281,700],{"nctId":706,"briefTitle":707,"status":55,"phases":1138,"primaryCompletion":709,"completion":131,"start":710,"enrollment":711,"conditions":1139,"interventions":1140},[41],[23],[277,278,714,279,280,281,700],{"trials":1142,"activeCount":8},[],{"trials":1144,"activeCount":8},[],{"intervention":444,"totalTrials":1101,"cells":1146},{"EARLY_PHASE1":1147,"PHASE1":1149,"PHASE2":1151,"PHASE3":1157,"PHASE4":1163,"NA":1165},{"trials":1148,"activeCount":8},[],{"trials":1150,"activeCount":8},[],{"trials":1152,"activeCount":8},[1153],{"nctId":435,"briefTitle":436,"status":55,"phases":1154,"primaryCompletion":438,"completion":438,"start":192,"enrollment":439,"conditions":1155,"interventions":1156},[40],[441],[90,443,444],{"trials":1158,"activeCount":8},[1159],{"nctId":479,"briefTitle":480,"status":55,"phases":1160,"primaryCompletion":482,"completion":58,"start":483,"enrollment":484,"conditions":1161,"interventions":1162},[41],[441],[90,444,264],{"trials":1164,"activeCount":8},[],{"trials":1166,"activeCount":8},[],{"intervention":1168,"totalTrials":1101,"cells":1169},"gefitinib",{"EARLY_PHASE1":1170,"PHASE1":1172,"PHASE2":1174,"PHASE3":1184,"PHASE4":1195,"NA":1197},{"trials":1171,"activeCount":8},[],{"trials":1173,"activeCount":8},[],{"trials":1175,"activeCount":8},[1176],{"nctId":1177,"briefTitle":1178,"status":55,"phases":1179,"primaryCompletion":1180,"completion":68,"start":1181,"enrollment":9,"conditions":1182,"interventions":1183},"NCT00025116","ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy",[40],"2003-06-05","2001-04-24",[23],[1168],{"trials":1185,"activeCount":8},[1186],{"nctId":1187,"briefTitle":1188,"status":270,"phases":1189,"primaryCompletion":204,"completion":204,"start":1190,"enrollment":1191,"conditions":1192,"interventions":1193},"NCT00352079","BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer",[41],"2007-01-04",41,[195],[1194,1168],"BCG vaccine",{"trials":1196,"activeCount":8},[],{"trials":1198,"activeCount":8},[],{"intervention":554,"totalTrials":1101,"cells":1200},{"EARLY_PHASE1":1201,"PHASE1":1203,"PHASE2":1205,"PHASE3":1211,"PHASE4":1217,"NA":1219},{"trials":1202,"activeCount":8},[],{"trials":1204,"activeCount":8},[],{"trials":1206,"activeCount":8},[1207],{"nctId":546,"briefTitle":547,"status":55,"phases":1208,"primaryCompletion":549,"completion":157,"start":550,"enrollment":551,"conditions":1209,"interventions":1210},[40],[441],[264,554],{"trials":1212,"activeCount":8},[1213],{"nctId":572,"briefTitle":573,"status":55,"phases":1214,"primaryCompletion":575,"completion":576,"start":577,"enrollment":578,"conditions":1215,"interventions":1216},[41],[441],[264,554],{"trials":1218,"activeCount":8},[],{"trials":1220,"activeCount":8},[],{"intervention":1222,"totalTrials":1101,"cells":1223},"cetuximab",{"EARLY_PHASE1":1224,"PHASE1":1226,"PHASE2":1228,"PHASE3":1230,"PHASE4":1251,"NA":1253},{"trials":1225,"activeCount":8},[],{"trials":1227,"activeCount":8},[],{"trials":1229,"activeCount":8},[],{"trials":1231,"activeCount":8},[1232,1241],{"nctId":1233,"briefTitle":1234,"status":55,"phases":1235,"primaryCompletion":1236,"completion":85,"start":1237,"enrollment":1238,"conditions":1239,"interventions":1240},"NCT00079066","Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer",[41],"2006-11-03","2003-12-30",572,[28,594],[1222],{"nctId":1242,"briefTitle":1243,"status":55,"phases":1244,"primaryCompletion":1245,"completion":131,"start":1246,"enrollment":1247,"conditions":1248,"interventions":1249},"NCT00640471","Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer",[41],"2011-09-06","2008-05-12",750,[28],[1222,1250],"brivanib alaninate",{"trials":1252,"activeCount":8},[],{"trials":1254,"activeCount":8},[],{"intervention":139,"totalTrials":1101,"cells":1256},{"EARLY_PHASE1":1257,"PHASE1":1259,"PHASE2":1261,"PHASE3":1273,"PHASE4":1279,"NA":1281},{"trials":1258,"activeCount":8},[],{"trials":1260,"activeCount":8},[],{"trials":1262,"activeCount":8},[1263],{"nctId":1264,"briefTitle":1265,"status":55,"phases":1266,"primaryCompletion":1267,"completion":58,"start":1268,"enrollment":1269,"conditions":1270,"interventions":1272},"NCT00003372","Topotecan in Treating Patients With Recurrent Brain Tumors",[40],"2000-10-05","1997-12-08",17,[1271],"Brain and Central Nervous System Tumors",[139],{"trials":1274,"activeCount":8},[1275],{"nctId":127,"briefTitle":128,"status":55,"phases":1276,"primaryCompletion":130,"completion":131,"start":132,"enrollment":133,"conditions":1277,"interventions":1278},[41],[135,31,136],[112,46,138,139],{"trials":1280,"activeCount":8},[],{"trials":1282,"activeCount":8},[],{"intervention":1284,"totalTrials":1101,"cells":1285},"Dacarbazine",{"EARLY_PHASE1":1286,"PHASE1":1288,"PHASE2":1290,"PHASE3":1303,"PHASE4":1309,"NA":1311},{"trials":1287,"activeCount":8},[],{"trials":1289,"activeCount":8},[],{"trials":1291,"activeCount":8},[1292],{"nctId":1293,"briefTitle":1294,"status":55,"phases":1295,"primaryCompletion":1296,"completion":623,"start":1297,"enrollment":1298,"conditions":1299,"interventions":1301},"NCT01152788","Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma",[40],"2014-11-25","2010-08-05",64,[1300],"Melanoma",[1302,1284],"rIL-21",{"trials":1304,"activeCount":8},[1305],{"nctId":1047,"briefTitle":1048,"status":55,"phases":1306,"primaryCompletion":1050,"completion":204,"start":1051,"enrollment":1052,"conditions":1307,"interventions":1308},[41],[1054],[1056,1057,528,1058],{"trials":1310,"activeCount":8},[],{"trials":1312,"activeCount":8},[],{"intervention":151,"totalTrials":1101,"cells":1314},{"EARLY_PHASE1":1315,"PHASE1":1317,"PHASE2":1319,"PHASE3":1332,"PHASE4":1338,"NA":1340},{"trials":1316,"activeCount":8},[],{"trials":1318,"activeCount":8},[],{"trials":1320,"activeCount":8},[1321],{"nctId":1322,"briefTitle":1323,"status":55,"phases":1324,"primaryCompletion":1325,"completion":131,"start":1326,"enrollment":1327,"conditions":1328,"interventions":1331},"NCT00516828","Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",[39,40],"2010-03-18","2007-11-27",21,[1329,1330],"Leukemia","Myelodysplastic Syndromes",[151],{"trials":1333,"activeCount":8},[1334],{"nctId":141,"briefTitle":142,"status":55,"phases":1335,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":1336,"interventions":1337},[41],[25],[150,46,151,90,75],{"trials":1339,"activeCount":8},[],{"trials":1341,"activeCount":8},[],{"intervention":76,"totalTrials":1101,"cells":1343},{"EARLY_PHASE1":1344,"PHASE1":1346,"PHASE2":1352,"PHASE3":1354,"PHASE4":1360,"NA":1362},{"trials":1345,"activeCount":8},[],{"trials":1347,"activeCount":8},[1348],{"nctId":64,"briefTitle":65,"status":55,"phases":1349,"primaryCompletion":67,"completion":68,"start":69,"enrollment":70,"conditions":1350,"interventions":1351},[39],[28,17],[73,46,74,75,76,77],{"trials":1353,"activeCount":8},[],{"trials":1355,"activeCount":8},[1356],{"nctId":836,"briefTitle":837,"status":55,"phases":1357,"primaryCompletion":839,"completion":85,"start":840,"enrollment":551,"conditions":1358,"interventions":1359},[41],[28],[74,76],{"trials":1361,"activeCount":8},[],{"trials":1363,"activeCount":8},[],{"intervention":164,"totalTrials":1101,"cells":1365},{"EARLY_PHASE1":1366,"PHASE1":1368,"PHASE2":1370,"PHASE3":1372,"PHASE4":1382,"NA":1384},{"trials":1367,"activeCount":8},[],{"trials":1369,"activeCount":8},[],{"trials":1371,"activeCount":8},[],{"trials":1373,"activeCount":8},[1374,1378],{"nctId":153,"briefTitle":154,"status":55,"phases":1375,"primaryCompletion":156,"completion":157,"start":158,"enrollment":159,"conditions":1376,"interventions":1377},[41],[14],[162,46,163,164,165],{"nctId":586,"briefTitle":587,"status":55,"phases":1379,"primaryCompletion":589,"completion":85,"start":590,"enrollment":591,"conditions":1380,"interventions":1381},[41],[593,23,594],[596,164,264],{"trials":1383,"activeCount":8},[],{"trials":1385,"activeCount":8},[],{"intervention":1387,"totalTrials":1388,"cells":1389},"BBI608",1,{"EARLY_PHASE1":1390,"PHASE1":1392,"PHASE2":1394,"PHASE3":1396,"PHASE4":1409,"NA":1411},{"trials":1391,"activeCount":8},[],{"trials":1393,"activeCount":8},[],{"trials":1395,"activeCount":8},[],{"trials":1397,"activeCount":8},[1398],{"nctId":1399,"briefTitle":1400,"status":55,"phases":1401,"primaryCompletion":1402,"completion":1403,"start":1404,"enrollment":1405,"conditions":1406,"interventions":1408},"NCT01830621","BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma",[41],"2016-05-07","2016-05-16","2013-05-10",282,[1407],"Colorectal Carcinoma",[1387],{"trials":1410,"activeCount":8},[],{"trials":1412,"activeCount":8},[],{"intervention":399,"totalTrials":1388,"cells":1414},{"EARLY_PHASE1":1415,"PHASE1":1417,"PHASE2":1419,"PHASE3":1421,"PHASE4":1427,"NA":1429},{"trials":1416,"activeCount":8},[],{"trials":1418,"activeCount":8},[],{"trials":1420,"activeCount":8},[],{"trials":1422,"activeCount":8},[1423],{"nctId":391,"briefTitle":392,"status":55,"phases":1424,"primaryCompletion":394,"completion":85,"start":395,"enrollment":396,"conditions":1425,"interventions":1426},[40,41],[17],[112,138,399],{"trials":1428,"activeCount":8},[],{"trials":1430,"activeCount":8},[],{"intervention":1432,"totalTrials":1388,"cells":1433},"anastrozole",{"EARLY_PHASE1":1434,"PHASE1":1436,"PHASE2":1438,"PHASE3":1440,"PHASE4":1452,"NA":1454},{"trials":1435,"activeCount":8},[],{"trials":1437,"activeCount":8},[],{"trials":1439,"activeCount":8},[],{"trials":1441,"activeCount":8},[1442],{"nctId":1443,"briefTitle":1444,"status":55,"phases":1445,"primaryCompletion":1446,"completion":204,"start":1447,"enrollment":1448,"conditions":1449,"interventions":1450},"NCT00066573","Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer",[41],"2010-11-07","2003-06-06",7576,[14],[1432,1451],"exemestane",{"trials":1453,"activeCount":8},[],{"trials":1455,"activeCount":8},[],{"intervention":1457,"totalTrials":1388,"cells":1458},"dextromethorphan hydrobromide",{"EARLY_PHASE1":1459,"PHASE1":1461,"PHASE2":1463,"PHASE3":1465,"PHASE4":1480,"NA":1482},{"trials":1460,"activeCount":8},[],{"trials":1462,"activeCount":8},[],{"trials":1464,"activeCount":8},[],{"trials":1466,"activeCount":8},[1467],{"nctId":1468,"briefTitle":1469,"status":55,"phases":1470,"primaryCompletion":1471,"completion":85,"start":1472,"enrollment":1473,"conditions":1474,"interventions":1478},"NCT00003687","Treatment for Chronic Pain in Patients With Advanced Cancer",[41],"2001-09-26","1998-06-11",87,[1475,1329,25,441,1330,593,1476,1477,20],"Chronic Myeloproliferative Disorders","Precancerous\u002FNonmalignant Condition","Small Intestine Cancer",[1457,1479],"morphine sulfate",{"trials":1481,"activeCount":8},[],{"trials":1483,"activeCount":8},[],{"intervention":1479,"totalTrials":1388,"cells":1485},{"EARLY_PHASE1":1486,"PHASE1":1488,"PHASE2":1490,"PHASE3":1492,"PHASE4":1498,"NA":1500},{"trials":1487,"activeCount":8},[],{"trials":1489,"activeCount":8},[],{"trials":1491,"activeCount":8},[],{"trials":1493,"activeCount":8},[1494],{"nctId":1468,"briefTitle":1469,"status":55,"phases":1495,"primaryCompletion":1471,"completion":85,"start":1472,"enrollment":1473,"conditions":1496,"interventions":1497},[41],[1475,1329,25,441,1330,593,1476,1477,20],[1457,1479],{"trials":1499,"activeCount":8},[],{"trials":1501,"activeCount":8},[],{"intervention":1503,"totalTrials":1388,"cells":1504},"marimastat",{"EARLY_PHASE1":1505,"PHASE1":1507,"PHASE2":1509,"PHASE3":1511,"PHASE4":1522,"NA":1524},{"trials":1506,"activeCount":8},[],{"trials":1508,"activeCount":8},[],{"trials":1510,"activeCount":8},[],{"trials":1512,"activeCount":8},[1513],{"nctId":1514,"briefTitle":1515,"status":55,"phases":1516,"primaryCompletion":1517,"completion":157,"start":1518,"enrollment":1519,"conditions":1520,"interventions":1521},"NCT00003011","Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer",[41],"2001-02-13","1997-01-31",555,[17],[1503],{"trials":1523,"activeCount":8},[],{"trials":1525,"activeCount":8},[],{"intervention":1527,"totalTrials":1388,"cells":1528},"alendronate sodium",{"EARLY_PHASE1":1529,"PHASE1":1531,"PHASE2":1533,"PHASE3":1535,"PHASE4":1549,"NA":1551},{"trials":1530,"activeCount":8},[],{"trials":1532,"activeCount":8},[],{"trials":1534,"activeCount":8},[],{"trials":1536,"activeCount":8},[1537],{"nctId":1538,"briefTitle":1539,"status":55,"phases":1540,"primaryCompletion":1541,"completion":204,"start":1542,"enrollment":1543,"conditions":1544,"interventions":1546},"NCT00354302","Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial",[41],"2011-03","2006-04-24",497,[14,1545],"Osteoporosis",[1527,1547,1548],"calcium gluconate","risedronate sodium",{"trials":1550,"activeCount":8},[],{"trials":1552,"activeCount":8},[],{"intervention":1547,"totalTrials":1388,"cells":1554},{"EARLY_PHASE1":1555,"PHASE1":1557,"PHASE2":1559,"PHASE3":1561,"PHASE4":1567,"NA":1569},{"trials":1556,"activeCount":8},[],{"trials":1558,"activeCount":8},[],{"trials":1560,"activeCount":8},[],{"trials":1562,"activeCount":8},[1563],{"nctId":1538,"briefTitle":1539,"status":55,"phases":1564,"primaryCompletion":1541,"completion":204,"start":1542,"enrollment":1543,"conditions":1565,"interventions":1566},[41],[14,1545],[1527,1547,1548],{"trials":1568,"activeCount":8},[],{"trials":1570,"activeCount":8},[],{"intervention":1548,"totalTrials":1388,"cells":1572},{"EARLY_PHASE1":1573,"PHASE1":1575,"PHASE2":1577,"PHASE3":1579,"PHASE4":1585,"NA":1587},{"trials":1574,"activeCount":8},[],{"trials":1576,"activeCount":8},[],{"trials":1578,"activeCount":8},[],{"trials":1580,"activeCount":8},[1581],{"nctId":1538,"briefTitle":1539,"status":55,"phases":1582,"primaryCompletion":1541,"completion":204,"start":1542,"enrollment":1543,"conditions":1583,"interventions":1584},[41],[14,1545],[1527,1547,1548],{"trials":1586,"activeCount":8},[],{"trials":1588,"activeCount":8},[],{"intervention":1194,"totalTrials":1388,"cells":1590},{"EARLY_PHASE1":1591,"PHASE1":1593,"PHASE2":1595,"PHASE3":1597,"PHASE4":1603,"NA":1605},{"trials":1592,"activeCount":8},[],{"trials":1594,"activeCount":8},[],{"trials":1596,"activeCount":8},[],{"trials":1598,"activeCount":8},[1599],{"nctId":1187,"briefTitle":1188,"status":270,"phases":1600,"primaryCompletion":204,"completion":204,"start":1190,"enrollment":1191,"conditions":1601,"interventions":1602},[41],[195],[1194,1168],{"trials":1604,"activeCount":8},[],{"trials":1606,"activeCount":8},[],{"intervention":997,"totalTrials":1388,"cells":1608},{"EARLY_PHASE1":1609,"PHASE1":1611,"PHASE2":1613,"PHASE3":1615,"PHASE4":1621,"NA":1623},{"trials":1610,"activeCount":8},[],{"trials":1612,"activeCount":8},[],{"trials":1614,"activeCount":8},[],{"trials":1616,"activeCount":8},[1617],{"nctId":989,"briefTitle":990,"status":55,"phases":1618,"primaryCompletion":992,"completion":239,"start":993,"enrollment":994,"conditions":1619,"interventions":1620},[41],[25],[150,997],{"trials":1622,"activeCount":8},[],{"trials":1624,"activeCount":8},[],{"intervention":1626,"totalTrials":1388,"cells":1627},"pilocarpine hydrochloride",{"EARLY_PHASE1":1628,"PHASE1":1630,"PHASE2":1632,"PHASE3":1634,"PHASE4":1645,"NA":1647},{"trials":1629,"activeCount":8},[],{"trials":1631,"activeCount":8},[],{"trials":1633,"activeCount":8},[],{"trials":1635,"activeCount":8},[1636],{"nctId":1637,"briefTitle":1638,"status":270,"phases":1639,"primaryCompletion":1640,"completion":157,"start":1641,"enrollment":602,"conditions":1642,"interventions":1644},"NCT00003686","Pilocarpine in Treating Patients With Dry Mouth Caused by Opioids",[41],"2007-11-01","1998-05-22",[1643,594],"Oral Complications",[1626],{"trials":1646,"activeCount":8},[],{"trials":1648,"activeCount":8},[],{"intervention":125,"totalTrials":1388,"cells":1650},{"EARLY_PHASE1":1651,"PHASE1":1653,"PHASE2":1655,"PHASE3":1657,"PHASE4":1663,"NA":1665},{"trials":1652,"activeCount":8},[],{"trials":1654,"activeCount":8},[],{"trials":1656,"activeCount":8},[],{"trials":1658,"activeCount":8},[1659],{"nctId":116,"briefTitle":117,"status":55,"phases":1660,"primaryCompletion":119,"completion":120,"start":121,"enrollment":122,"conditions":1661,"interventions":1662},[41],[34],[125,46],{"trials":1664,"activeCount":8},[],{"trials":1666,"activeCount":8},[],{"intervention":777,"totalTrials":1388,"cells":1668},{"EARLY_PHASE1":1669,"PHASE1":1671,"PHASE2":1673,"PHASE3":1675,"PHASE4":1681,"NA":1683},{"trials":1670,"activeCount":8},[],{"trials":1672,"activeCount":8},[],{"trials":1674,"activeCount":8},[],{"trials":1676,"activeCount":8},[1677],{"nctId":768,"briefTitle":769,"status":55,"phases":1678,"primaryCompletion":771,"completion":772,"start":773,"enrollment":774,"conditions":1679,"interventions":1680},[41],[14],[777,163,528,222,74,778,165],{"trials":1682,"activeCount":8},[],{"trials":1684,"activeCount":8},[],{"intervention":778,"totalTrials":1388,"cells":1686},{"EARLY_PHASE1":1687,"PHASE1":1689,"PHASE2":1691,"PHASE3":1693,"PHASE4":1699,"NA":1701},{"trials":1688,"activeCount":8},[],{"trials":1690,"activeCount":8},[],{"trials":1692,"activeCount":8},[],{"trials":1694,"activeCount":8},[1695],{"nctId":768,"briefTitle":769,"status":55,"phases":1696,"primaryCompletion":771,"completion":772,"start":773,"enrollment":774,"conditions":1697,"interventions":1698},[41],[14],[777,163,528,222,74,778,165],{"trials":1700,"activeCount":8},[],{"trials":1702,"activeCount":8},[],{"intervention":714,"totalTrials":1388,"cells":1704},{"EARLY_PHASE1":1705,"PHASE1":1707,"PHASE2":1709,"PHASE3":1711,"PHASE4":1717,"NA":1719},{"trials":1706,"activeCount":8},[],{"trials":1708,"activeCount":8},[],{"trials":1710,"activeCount":8},[],{"trials":1712,"activeCount":8},[1713],{"nctId":706,"briefTitle":707,"status":55,"phases":1714,"primaryCompletion":709,"completion":131,"start":710,"enrollment":711,"conditions":1715,"interventions":1716},[41],[23],[277,278,714,279,280,281,700],{"trials":1718,"activeCount":8},[],{"trials":1720,"activeCount":8},[],{"intervention":1056,"totalTrials":1388,"cells":1722},{"EARLY_PHASE1":1723,"PHASE1":1725,"PHASE2":1727,"PHASE3":1729,"PHASE4":1735,"NA":1737},{"trials":1724,"activeCount":8},[],{"trials":1726,"activeCount":8},[],{"trials":1728,"activeCount":8},[],{"trials":1730,"activeCount":8},[1731],{"nctId":1047,"briefTitle":1048,"status":55,"phases":1732,"primaryCompletion":1050,"completion":204,"start":1051,"enrollment":1052,"conditions":1733,"interventions":1734},[41],[1054],[1056,1057,528,1058],{"trials":1736,"activeCount":8},[],{"trials":1738,"activeCount":8},[],{"intervention":1058,"totalTrials":1388,"cells":1740},{"EARLY_PHASE1":1741,"PHASE1":1743,"PHASE2":1745,"PHASE3":1747,"PHASE4":1753,"NA":1755},{"trials":1742,"activeCount":8},[],{"trials":1744,"activeCount":8},[],{"trials":1746,"activeCount":8},[],{"trials":1748,"activeCount":8},[1749],{"nctId":1047,"briefTitle":1048,"status":55,"phases":1750,"primaryCompletion":1050,"completion":204,"start":1051,"enrollment":1052,"conditions":1751,"interventions":1752},[41],[1054],[1056,1057,528,1058],{"trials":1754,"activeCount":8},[],{"trials":1756,"activeCount":8},[],{"intervention":477,"totalTrials":1388,"cells":1758},{"EARLY_PHASE1":1759,"PHASE1":1761,"PHASE2":1763,"PHASE3":1765,"PHASE4":1771,"NA":1773},{"trials":1760,"activeCount":8},[],{"trials":1762,"activeCount":8},[],{"trials":1764,"activeCount":8},[],{"trials":1766,"activeCount":8},[1767],{"nctId":468,"briefTitle":469,"status":55,"phases":1768,"primaryCompletion":471,"completion":85,"start":472,"enrollment":473,"conditions":1769,"interventions":1770},[41],[475],[90,477],{"trials":1772,"activeCount":8},[],{"trials":1774,"activeCount":8},[],{"intervention":1250,"totalTrials":1388,"cells":1776},{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1781,"PHASE3":1783,"PHASE4":1789,"NA":1791},{"trials":1778,"activeCount":8},[],{"trials":1780,"activeCount":8},[],{"trials":1782,"activeCount":8},[],{"trials":1784,"activeCount":8},[1785],{"nctId":1242,"briefTitle":1243,"status":55,"phases":1786,"primaryCompletion":1245,"completion":131,"start":1246,"enrollment":1247,"conditions":1787,"interventions":1788},[41],[28],[1222,1250],{"trials":1790,"activeCount":8},[],{"trials":1792,"activeCount":8},[],{"intervention":175,"totalTrials":1388,"cells":1794},{"EARLY_PHASE1":1795,"PHASE1":1797,"PHASE2":1799,"PHASE3":1801,"PHASE4":1807,"NA":1809},{"trials":1796,"activeCount":8},[],{"trials":1798,"activeCount":8},[],{"trials":1800,"activeCount":8},[],{"trials":1802,"activeCount":8},[1803],{"nctId":167,"briefTitle":168,"status":55,"phases":1804,"primaryCompletion":170,"completion":58,"start":171,"enrollment":172,"conditions":1805,"interventions":1806},[41],[17],[46,175],{"trials":1808,"activeCount":8},[],{"trials":1810,"activeCount":8},[],{"intervention":1095,"totalTrials":1388,"cells":1812},{"EARLY_PHASE1":1813,"PHASE1":1815,"PHASE2":1817,"PHASE3":1819,"PHASE4":1825,"NA":1827},{"trials":1814,"activeCount":8},[],{"trials":1816,"activeCount":8},[],{"trials":1818,"activeCount":8},[],{"trials":1820,"activeCount":8},[1821],{"nctId":1086,"briefTitle":1087,"status":55,"phases":1822,"primaryCompletion":1089,"completion":1090,"start":1091,"enrollment":1092,"conditions":1823,"interventions":1824},[41],[14],[1095,165],{"trials":1826,"activeCount":8},[],{"trials":1828,"activeCount":8},[],{"intervention":1830,"totalTrials":1388,"cells":1831},"theophylline",{"EARLY_PHASE1":1832,"PHASE1":1834,"PHASE2":1836,"PHASE3":1838,"PHASE4":1848,"NA":1850},{"trials":1833,"activeCount":8},[],{"trials":1835,"activeCount":8},[],{"trials":1837,"activeCount":8},[],{"trials":1839,"activeCount":8},[1840],{"nctId":1841,"briefTitle":1842,"status":55,"phases":1843,"primaryCompletion":157,"completion":157,"start":1844,"enrollment":852,"conditions":1845,"interventions":1847},"NCT00003684","Theophylline in Treating Cancer Patients With Shortness of Breath",[41],"1998-03-24",[1846,594,20],"Pulmonary Complications",[1830],{"trials":1849,"activeCount":8},[],{"trials":1851,"activeCount":8},[],{"intervention":1853,"totalTrials":1388,"cells":1854},"PF-00299804",{"EARLY_PHASE1":1855,"PHASE1":1857,"PHASE2":1859,"PHASE3":1861,"PHASE4":1872,"NA":1874},{"trials":1856,"activeCount":8},[],{"trials":1858,"activeCount":8},[],{"trials":1860,"activeCount":8},[],{"trials":1862,"activeCount":8},[1863],{"nctId":1864,"briefTitle":1865,"status":55,"phases":1866,"primaryCompletion":1867,"completion":456,"start":1868,"enrollment":1869,"conditions":1870,"interventions":1871},"NCT01000025","PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer",[41],"2014-01-15","2009-12-23",720,[17],[1853],{"trials":1873,"activeCount":8},[],{"trials":1875,"activeCount":8},[],{"intervention":596,"totalTrials":1388,"cells":1877},{"EARLY_PHASE1":1878,"PHASE1":1880,"PHASE2":1882,"PHASE3":1884,"PHASE4":1890,"NA":1892},{"trials":1879,"activeCount":8},[],{"trials":1881,"activeCount":8},[],{"trials":1883,"activeCount":8},[],{"trials":1885,"activeCount":8},[1886],{"nctId":586,"briefTitle":587,"status":55,"phases":1887,"primaryCompletion":589,"completion":85,"start":590,"enrollment":591,"conditions":1888,"interventions":1889},[41],[593,23,594],[596,164,264],{"trials":1891,"activeCount":8},[],{"trials":1893,"activeCount":8},[],{"intervention":527,"totalTrials":1388,"cells":1895},{"EARLY_PHASE1":1896,"PHASE1":1898,"PHASE2":1900,"PHASE3":1902,"PHASE4":1908,"NA":1910},{"trials":1897,"activeCount":8},[],{"trials":1899,"activeCount":8},[],{"trials":1901,"activeCount":8},[],{"trials":1903,"activeCount":8},[1904],{"nctId":518,"briefTitle":519,"status":55,"phases":1905,"primaryCompletion":521,"completion":522,"start":523,"enrollment":524,"conditions":1906,"interventions":1907},[41],[14],[527,162,163,528,222,74,138],{"trials":1909,"activeCount":8},[],{"trials":1911,"activeCount":8},[],{"intervention":198,"totalTrials":602,"cells":1913},{"EARLY_PHASE1":1914,"PHASE1":1916,"PHASE2":1926,"PHASE3":1936,"PHASE4":1938,"NA":1940},{"trials":1915,"activeCount":8},[],{"trials":1917,"activeCount":8},[1918,1922],{"nctId":189,"briefTitle":190,"status":55,"phases":1919,"primaryCompletion":192,"completion":58,"start":193,"enrollment":9,"conditions":1920,"interventions":1921},[39],[195,14,196,17,31,23,20],[198,181],{"nctId":679,"briefTitle":680,"status":55,"phases":1923,"primaryCompletion":682,"completion":68,"start":683,"enrollment":684,"conditions":1924,"interventions":1925},[39],[23],[278,198,279],{"trials":1927,"activeCount":8},[1928,1932],{"nctId":246,"briefTitle":247,"status":55,"phases":1929,"primaryCompletion":249,"completion":68,"start":250,"enrollment":251,"conditions":1930,"interventions":1931},[40],[14],[198,181],{"nctId":255,"briefTitle":256,"status":55,"phases":1933,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":1934,"interventions":1935},[40],[23],[198,181,264],{"trials":1937,"activeCount":8},[],{"trials":1939,"activeCount":8},[],{"trials":1941,"activeCount":8},[],{"intervention":313,"totalTrials":602,"cells":1943},{"EARLY_PHASE1":1944,"PHASE1":1946,"PHASE2":1948,"PHASE3":1976,"PHASE4":1978,"NA":1980},{"trials":1945,"activeCount":8},[],{"trials":1947,"activeCount":8},[],{"trials":1949,"activeCount":8},[1950,1954,1963,1967],{"nctId":304,"briefTitle":305,"status":55,"phases":1951,"primaryCompletion":307,"completion":308,"start":309,"enrollment":310,"conditions":1952,"interventions":1953},[40],[25],[313,75],{"nctId":1955,"briefTitle":1956,"status":55,"phases":1957,"primaryCompletion":1958,"completion":1959,"start":1960,"enrollment":206,"conditions":1961,"interventions":1962},"NCT00045695","Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia",[40],"2006-03","2009-12","2002-08",[25],[313],{"nctId":560,"briefTitle":561,"status":55,"phases":1964,"primaryCompletion":563,"completion":204,"start":564,"enrollment":565,"conditions":1965,"interventions":1966},[40],[25],[150,313,163,264,568],{"nctId":1968,"briefTitle":1969,"status":55,"phases":1970,"primaryCompletion":1971,"completion":58,"start":1972,"enrollment":1973,"conditions":1974,"interventions":1975},"NCT00030875","Bortezomib in Treating Patients With Mantle Cell Lymphoma",[40],"2005-07-21","2002-11-19",30,[25],[313],{"trials":1977,"activeCount":8},[],{"trials":1979,"activeCount":8},[],{"trials":1981,"activeCount":8},[],{"intervention":1983,"totalTrials":852,"cells":1984},"alvocidib",{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":1989,"PHASE3":2017,"PHASE4":2019,"NA":2021},{"trials":1986,"activeCount":8},[],{"trials":1988,"activeCount":8},[],{"trials":1990,"activeCount":8},[1991,2001,2009],{"nctId":1992,"briefTitle":1993,"status":55,"phases":1994,"primaryCompletion":1995,"completion":68,"start":1996,"enrollment":1997,"conditions":1998,"interventions":2000},"NCT00005974","Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma",[40],"2002-11-07","2000-07-04",18,[1999],"Sarcoma",[1983],{"nctId":2002,"briefTitle":2003,"status":55,"phases":2004,"primaryCompletion":2005,"completion":68,"start":2006,"enrollment":954,"conditions":2007,"interventions":2008},"NCT00005074","Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma",[40],"2002-02-20","2000-01-24",[25],[1983],{"nctId":2010,"briefTitle":2011,"status":55,"phases":2012,"primaryCompletion":2013,"completion":58,"start":1996,"enrollment":1269,"conditions":2014,"interventions":2016},"NCT00005971","Flavopiridol in Treating Patients With Metastatic Malignant Melanoma",[40],"2001-08-24",[2015],"Melanoma (Skin)",[1983],{"trials":2018,"activeCount":8},[],{"trials":2020,"activeCount":8},[],{"trials":2022,"activeCount":8},[],{"intervention":62,"totalTrials":852,"cells":2024},{"EARLY_PHASE1":2025,"PHASE1":2027,"PHASE2":2042,"PHASE3":2053,"PHASE4":2055,"NA":2057},{"trials":2026,"activeCount":8},[],{"trials":2028,"activeCount":8},[2029,2038],{"nctId":2030,"briefTitle":2031,"status":55,"phases":2032,"primaryCompletion":2033,"completion":68,"start":2034,"enrollment":2035,"conditions":2036,"interventions":2037},"NCT00003891","Lurtotecan Liposome in Treating Patients With Advanced Solid Tumors",[39],"2001-06-08","1999-02-25",37,[20],[62],{"nctId":53,"briefTitle":54,"status":55,"phases":2039,"primaryCompletion":57,"completion":58,"start":59,"enrollment":18,"conditions":2040,"interventions":2041},[39],[34,17,31,20],[46,62],{"trials":2043,"activeCount":8},[2044],{"nctId":2045,"briefTitle":2046,"status":55,"phases":2047,"primaryCompletion":2048,"completion":68,"start":2049,"enrollment":2050,"conditions":2051,"interventions":2052},"NCT00010179","Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer",[40],"2002-10-22","2000-10-31",81,[135,31,136],[62],{"trials":2054,"activeCount":8},[],{"trials":2056,"activeCount":8},[],{"trials":2058,"activeCount":8},[],{"intervention":2060,"totalTrials":1101,"cells":2061},"HDAC inhibitor SB939",{"EARLY_PHASE1":2062,"PHASE1":2064,"PHASE2":2075,"PHASE3":2086,"PHASE4":2088,"NA":2090},{"trials":2063,"activeCount":8},[],{"trials":2065,"activeCount":8},[2066],{"nctId":2067,"briefTitle":2068,"status":55,"phases":2069,"primaryCompletion":2070,"completion":308,"start":2071,"enrollment":2072,"conditions":2073,"interventions":2074},"NCT00504296","SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors",[39],"2010-04-22","2007-09-14",39,[20],[2060],{"trials":2076,"activeCount":8},[2077],{"nctId":2078,"briefTitle":2079,"status":55,"phases":2080,"primaryCompletion":2081,"completion":623,"start":2082,"enrollment":2083,"conditions":2084,"interventions":2085},"NCT01075308","SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer",[40],"2015-01-05","2010-06-28",32,[23],[2060],{"trials":2087,"activeCount":8},[],{"trials":2089,"activeCount":8},[],{"trials":2091,"activeCount":8},[],{"intervention":2093,"totalTrials":1101,"cells":2094},"ispinesib",{"EARLY_PHASE1":2095,"PHASE1":2097,"PHASE2":2099,"PHASE3":2117,"PHASE4":2119,"NA":2121},{"trials":2096,"activeCount":8},[],{"trials":2098,"activeCount":8},[],{"trials":2100,"activeCount":8},[2101,2108],{"nctId":2102,"briefTitle":2103,"status":55,"phases":2104,"primaryCompletion":227,"completion":68,"start":2105,"enrollment":251,"conditions":2106,"interventions":2107},"NCT00095992","SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer",[40],"2005-03-08",[349],[2093],{"nctId":2109,"briefTitle":2110,"status":55,"phases":2111,"primaryCompletion":2112,"completion":2113,"start":2114,"enrollment":1269,"conditions":2115,"interventions":2116},"NCT00095953","SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma",[40],"2006-09","2008-09","2004-11",[2015],[2093],{"trials":2118,"activeCount":8},[],{"trials":2120,"activeCount":8},[],{"trials":2122,"activeCount":8},[],{"intervention":2124,"totalTrials":1101,"cells":2125},"SarCNU",{"EARLY_PHASE1":2126,"PHASE1":2128,"PHASE2":2130,"PHASE3":2147,"PHASE4":2149,"NA":2151},{"trials":2127,"activeCount":8},[],{"trials":2129,"activeCount":8},[],{"trials":2131,"activeCount":8},[2132,2140],{"nctId":2133,"briefTitle":2134,"status":55,"phases":2135,"primaryCompletion":2136,"completion":68,"start":2137,"enrollment":1997,"conditions":2138,"interventions":2139},"NCT00028015","SarCNU in Treating Patients With Recurrent or Metastatic Colorectal Cancer",[40],"2003-09-22","2001-10-30",[28],[2124],{"nctId":2141,"briefTitle":2142,"status":55,"phases":2143,"primaryCompletion":2144,"completion":68,"start":381,"enrollment":11,"conditions":2145,"interventions":2146},"NCT00036660","SarCNU in Treating Patients With Recurrent Malignant Glioma",[40],"2003-04-15",[1271],[2124],{"trials":2148,"activeCount":8},[],{"trials":2150,"activeCount":8},[],{"trials":2152,"activeCount":8},[],{"intervention":2154,"totalTrials":1101,"cells":2155},"Foretinib",{"EARLY_PHASE1":2156,"PHASE1":2158,"PHASE2":2160,"PHASE3":2181,"PHASE4":2183,"NA":2185},{"trials":2157,"activeCount":8},[],{"trials":2159,"activeCount":8},[],{"trials":2161,"activeCount":8},[2162,2171],{"nctId":2163,"briefTitle":2164,"status":55,"phases":2165,"primaryCompletion":2166,"completion":623,"start":2167,"enrollment":15,"conditions":2168,"interventions":2169},"NCT01138384","Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer",[39,40],"2014-05-14","2010-10-27",[14],[2154,2170],"Lapatinib",{"nctId":2172,"briefTitle":2173,"status":55,"phases":2174,"primaryCompletion":2175,"completion":623,"start":2176,"enrollment":2177,"conditions":2178,"interventions":2180},"NCT01147484","A Study of Foretinib in Patients With Recurrent\u002FMetastatic Breast Cancer",[40],"2014-12-14","2010-09-02",47,[2179],"Recurrent Breast Cancer",[2154],{"trials":2182,"activeCount":8},[],{"trials":2184,"activeCount":8},[],{"trials":2186,"activeCount":8},[],{"intervention":2188,"totalTrials":1101,"cells":2189},"AT7519M",{"EARLY_PHASE1":2190,"PHASE1":2192,"PHASE2":2194,"PHASE3":2213,"PHASE4":2215,"NA":2217},{"trials":2191,"activeCount":8},[],{"trials":2193,"activeCount":8},[],{"trials":2195,"activeCount":8},[2196,2204],{"nctId":2197,"briefTitle":2198,"status":55,"phases":2199,"primaryCompletion":622,"completion":623,"start":2200,"enrollment":29,"conditions":2201,"interventions":2203},"NCT01627054","A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and\u002For Refractory Chronic Lymphocytic Leukemia",[40],"2012-08-27",[2202],"Chronic Lymphocytic Leukemia",[2188],{"nctId":2205,"briefTitle":2206,"status":55,"phases":2207,"primaryCompletion":2208,"completion":623,"start":2209,"enrollment":98,"conditions":2210,"interventions":2212},"NCT01652144","A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma",[40],"2014-12-02","2012-09-14",[2211],"Mantle Cell Lymphoma",[2188],{"trials":2214,"activeCount":8},[],{"trials":2216,"activeCount":8},[],{"trials":2218,"activeCount":8},[],{"intervention":2220,"totalTrials":1101,"cells":2221},"SB939",{"EARLY_PHASE1":2222,"PHASE1":2224,"PHASE2":2235,"PHASE3":2247,"PHASE4":2249,"NA":2251},{"trials":2223,"activeCount":8},[],{"trials":2225,"activeCount":8},[2226],{"nctId":2227,"briefTitle":2228,"status":55,"phases":2229,"primaryCompletion":2230,"completion":239,"start":2231,"enrollment":98,"conditions":2232,"interventions":2234},"NCT01184274","A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia",[39],"2012-04-12","2010-10-01",[1329,2233],"Solid Tumours",[2220],{"trials":2236,"activeCount":8},[2237],{"nctId":2238,"briefTitle":2239,"status":55,"phases":2240,"primaryCompletion":2241,"completion":239,"start":2242,"enrollment":2243,"conditions":2244,"interventions":2246},"NCT01112384","A Study of SB939 in Patients With Translocation-Associated Recurrent\u002FMetastatic Sarcomas",[40],"2013-01-21","2010-10-21",24,[2245],"Metastatic Sarcoma",[2220],{"trials":2248,"activeCount":8},[],{"trials":2250,"activeCount":8},[],{"trials":2252,"activeCount":8},[],{"intervention":2254,"totalTrials":1101,"cells":2255},"everolimus",{"EARLY_PHASE1":2256,"PHASE1":2258,"PHASE2":2270,"PHASE3":2281,"PHASE4":2283,"NA":2285},{"trials":2257,"activeCount":8},[],{"trials":2259,"activeCount":8},[2260],{"nctId":2261,"briefTitle":2262,"status":55,"phases":2263,"primaryCompletion":2264,"completion":204,"start":2265,"enrollment":2083,"conditions":2266,"interventions":2267},"NCT00387400","Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme",[39],"2010-09-24","2007-03-20",[1271],[2254,2268,2269],"temozolomide","microarray analysis",{"trials":2271,"activeCount":8},[2272],{"nctId":2273,"briefTitle":2274,"status":55,"phases":2275,"primaryCompletion":2276,"completion":259,"start":2277,"enrollment":2278,"conditions":2279,"interventions":2280},"NCT00255788","Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer",[40],"2008-07-22","2005-05-10",49,[14],[2254],{"trials":2282,"activeCount":8},[],{"trials":2284,"activeCount":8},[],{"trials":2286,"activeCount":8},[],{"intervention":2288,"totalTrials":1101,"cells":2289},"PX-866",{"EARLY_PHASE1":2290,"PHASE1":2292,"PHASE2":2294,"PHASE3":2313,"PHASE4":2315,"NA":2317},{"trials":2291,"activeCount":8},[],{"trials":2293,"activeCount":8},[],{"trials":2295,"activeCount":8},[2296,2305],{"nctId":2297,"briefTitle":2298,"status":55,"phases":2299,"primaryCompletion":2300,"completion":623,"start":2301,"enrollment":109,"conditions":2302,"interventions":2304},"NCT01259869","A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression",[40],"2014-10-29","2011-04-01",[2303],"Glioblastoma",[2288],{"nctId":2306,"briefTitle":2307,"status":55,"phases":2308,"primaryCompletion":2309,"completion":456,"start":2310,"enrollment":945,"conditions":2311,"interventions":2312},"NCT01331083","A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer",[40],"2015-01-13","2011-09-09",[23],[2288],{"trials":2314,"activeCount":8},[],{"trials":2316,"activeCount":8},[],{"trials":2318,"activeCount":8},[],{"intervention":2320,"totalTrials":1101,"cells":2321},"perifosine",{"EARLY_PHASE1":2322,"PHASE1":2324,"PHASE2":2326,"PHASE3":2344,"PHASE4":2346,"NA":2348},{"trials":2323,"activeCount":8},[],{"trials":2325,"activeCount":8},[],{"trials":2327,"activeCount":8},[2328,2336],{"nctId":2329,"briefTitle":2330,"status":55,"phases":2331,"primaryCompletion":2332,"completion":68,"start":2333,"enrollment":1269,"conditions":2334,"interventions":2335},"NCT00053794","Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma",[40],"2004-09-18","2003-06-09",[956,1999],[2320],{"nctId":2337,"briefTitle":2338,"status":55,"phases":2339,"primaryCompletion":2340,"completion":58,"start":2341,"enrollment":1997,"conditions":2342,"interventions":2343},"NCT00053781","Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma",[40],"2004-09-14","2003-06-20",[2015],[2320],{"trials":2345,"activeCount":8},[],{"trials":2347,"activeCount":8},[],{"trials":2349,"activeCount":8},[],{"intervention":443,"totalTrials":1388,"cells":2351},{"EARLY_PHASE1":2352,"PHASE1":2354,"PHASE2":2356,"PHASE3":2362,"PHASE4":2364,"NA":2366},{"trials":2353,"activeCount":8},[],{"trials":2355,"activeCount":8},[],{"trials":2357,"activeCount":8},[2358],{"nctId":435,"briefTitle":436,"status":55,"phases":2359,"primaryCompletion":438,"completion":438,"start":192,"enrollment":439,"conditions":2360,"interventions":2361},[40],[441],[90,443,444],{"trials":2363,"activeCount":8},[],{"trials":2365,"activeCount":8},[],{"trials":2367,"activeCount":8},[],{"intervention":627,"totalTrials":1388,"cells":2369},{"EARLY_PHASE1":2370,"PHASE1":2372,"PHASE2":2374,"PHASE3":2380,"PHASE4":2382,"NA":2384},{"trials":2371,"activeCount":8},[],{"trials":2373,"activeCount":8},[],{"trials":2375,"activeCount":8},[2376],{"nctId":619,"briefTitle":620,"status":55,"phases":2377,"primaryCompletion":622,"completion":623,"start":624,"enrollment":70,"conditions":2378,"interventions":2379},[39,40],[17],[627,339],{"trials":2381,"activeCount":8},[],{"trials":2383,"activeCount":8},[],{"trials":2385,"activeCount":8},[],{"intervention":2170,"totalTrials":1388,"cells":2387},{"EARLY_PHASE1":2388,"PHASE1":2390,"PHASE2":2392,"PHASE3":2398,"PHASE4":2400,"NA":2402},{"trials":2389,"activeCount":8},[],{"trials":2391,"activeCount":8},[],{"trials":2393,"activeCount":8},[2394],{"nctId":2163,"briefTitle":2164,"status":55,"phases":2395,"primaryCompletion":2166,"completion":623,"start":2167,"enrollment":15,"conditions":2396,"interventions":2397},[39,40],[14],[2154,2170],{"trials":2399,"activeCount":8},[],{"trials":2401,"activeCount":8},[],{"trials":2403,"activeCount":8},[],{"intervention":2405,"totalTrials":1388,"cells":2406},"ISIS 5132",{"EARLY_PHASE1":2407,"PHASE1":2409,"PHASE2":2411,"PHASE3":2422,"PHASE4":2424,"NA":2426},{"trials":2408,"activeCount":8},[],{"trials":2410,"activeCount":8},[],{"trials":2412,"activeCount":8},[2413],{"nctId":2414,"briefTitle":2415,"status":55,"phases":2416,"primaryCompletion":2417,"completion":68,"start":2418,"enrollment":2419,"conditions":2420,"interventions":2421},"NCT00003892","ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer",[40],"2000-10-17","1999-02-01",22,[31],[2405],{"trials":2423,"activeCount":8},[],{"trials":2425,"activeCount":8},[],{"trials":2427,"activeCount":8},[],{"intervention":2429,"totalTrials":1388,"cells":2430},"sorafenib tosylate",{"EARLY_PHASE1":2431,"PHASE1":2433,"PHASE2":2435,"PHASE3":2446,"PHASE4":2448,"NA":2450},{"trials":2432,"activeCount":8},[],{"trials":2434,"activeCount":8},[],{"trials":2436,"activeCount":8},[2437],{"nctId":2438,"briefTitle":2439,"status":55,"phases":2440,"primaryCompletion":2441,"completion":259,"start":2442,"enrollment":2443,"conditions":2444,"interventions":2445},"NCT00093457","Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer",[40],"2006-09-28","2004-08-10",28,[23],[2429],{"trials":2447,"activeCount":8},[],{"trials":2449,"activeCount":8},[],{"trials":2451,"activeCount":8},[],{"intervention":101,"totalTrials":1388,"cells":2453},{"EARLY_PHASE1":2454,"PHASE1":2456,"PHASE2":2458,"PHASE3":2464,"PHASE4":2466,"NA":2468},{"trials":2455,"activeCount":8},[],{"trials":2457,"activeCount":8},[],{"trials":2459,"activeCount":8},[2460],{"nctId":92,"briefTitle":93,"status":55,"phases":2461,"primaryCompletion":95,"completion":96,"start":97,"enrollment":98,"conditions":2462,"interventions":2463},[39,40],[17],[101,46,102],{"trials":2465,"activeCount":8},[],{"trials":2467,"activeCount":8},[],{"trials":2469,"activeCount":8},[],{"intervention":102,"totalTrials":1388,"cells":2471},{"EARLY_PHASE1":2472,"PHASE1":2474,"PHASE2":2476,"PHASE3":2482,"PHASE4":2484,"NA":2486},{"trials":2473,"activeCount":8},[],{"trials":2475,"activeCount":8},[],{"trials":2477,"activeCount":8},[2478],{"nctId":92,"briefTitle":93,"status":55,"phases":2479,"primaryCompletion":95,"completion":96,"start":97,"enrollment":98,"conditions":2480,"interventions":2481},[39,40],[17],[101,46,102],{"trials":2483,"activeCount":8},[],{"trials":2485,"activeCount":8},[],{"trials":2487,"activeCount":8},[],{"intervention":2489,"totalTrials":1388,"cells":2490},"fludarabine phosphate",{"EARLY_PHASE1":2491,"PHASE1":2493,"PHASE2":2495,"PHASE3":2506,"PHASE4":2508,"NA":2510},{"trials":2492,"activeCount":8},[],{"trials":2494,"activeCount":8},[],{"trials":2496,"activeCount":8},[2497],{"nctId":2498,"briefTitle":2499,"status":55,"phases":2500,"primaryCompletion":2501,"completion":58,"start":2502,"enrollment":2503,"conditions":2504,"interventions":2505},"NCT00049075","Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia",[40],"2005-07-22","2002-08-08",128,[1329],[2489],{"trials":2507,"activeCount":8},[],{"trials":2509,"activeCount":8},[],{"trials":2511,"activeCount":8},[],{"intervention":2513,"totalTrials":1388,"cells":2514},"recombinant human interleukin-21",{"EARLY_PHASE1":2515,"PHASE1":2517,"PHASE2":2519,"PHASE3":2528,"PHASE4":2530,"NA":2532},{"trials":2516,"activeCount":8},[],{"trials":2518,"activeCount":8},[],{"trials":2520,"activeCount":8},[2521],{"nctId":2522,"briefTitle":2523,"status":55,"phases":2524,"primaryCompletion":2176,"completion":96,"start":2525,"enrollment":9,"conditions":2526,"interventions":2527},"NCT00514085","Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma",[40],"2007-12-13",[2015],[2513],{"trials":2529,"activeCount":8},[],{"trials":2531,"activeCount":8},[],{"trials":2533,"activeCount":8},[],{"intervention":1302,"totalTrials":1388,"cells":2535},{"EARLY_PHASE1":2536,"PHASE1":2538,"PHASE2":2540,"PHASE3":2546,"PHASE4":2548,"NA":2550},{"trials":2537,"activeCount":8},[],{"trials":2539,"activeCount":8},[],{"trials":2541,"activeCount":8},[2542],{"nctId":1293,"briefTitle":1294,"status":55,"phases":2543,"primaryCompletion":1296,"completion":623,"start":1297,"enrollment":1298,"conditions":2544,"interventions":2545},[40],[1300],[1302,1284],{"trials":2547,"activeCount":8},[],{"trials":2549,"activeCount":8},[],{"trials":2551,"activeCount":8},[],{"intervention":2553,"totalTrials":1388,"cells":2554},"ridaforolimus",{"EARLY_PHASE1":2555,"PHASE1":2557,"PHASE2":2559,"PHASE3":2571,"PHASE4":2573,"NA":2575},{"trials":2556,"activeCount":8},[],{"trials":2558,"activeCount":8},[],{"trials":2560,"activeCount":8},[2561],{"nctId":2562,"briefTitle":2563,"status":55,"phases":2564,"primaryCompletion":2565,"completion":623,"start":2566,"enrollment":2567,"conditions":2568,"interventions":2569},"NCT00770185","Ridaforolimus in Treating Patients With Recurrent Metastatic and\u002For Locally Advanced Endometrial Cancer",[40],"2012-03-19","2008-11-13",35,[956],[2553,2570],"gene expression analysis",{"trials":2572,"activeCount":8},[],{"trials":2574,"activeCount":8},[],{"trials":2576,"activeCount":8},[],{"intervention":2570,"totalTrials":1388,"cells":2578},{"EARLY_PHASE1":2579,"PHASE1":2581,"PHASE2":2583,"PHASE3":2589,"PHASE4":2591,"NA":2593},{"trials":2580,"activeCount":8},[],{"trials":2582,"activeCount":8},[],{"trials":2584,"activeCount":8},[2585],{"nctId":2562,"briefTitle":2563,"status":55,"phases":2586,"primaryCompletion":2565,"completion":623,"start":2566,"enrollment":2567,"conditions":2587,"interventions":2588},[40],[956],[2553,2570],{"trials":2590,"activeCount":8},[],{"trials":2592,"activeCount":8},[],{"trials":2594,"activeCount":8},[],{"intervention":2596,"totalTrials":1388,"cells":2597},"triapine",{"EARLY_PHASE1":2598,"PHASE1":2600,"PHASE2":2602,"PHASE3":2612,"PHASE4":2614,"NA":2616},{"trials":2599,"activeCount":8},[],{"trials":2601,"activeCount":8},[],{"trials":2603,"activeCount":8},[2604],{"nctId":2605,"briefTitle":2606,"status":55,"phases":2607,"primaryCompletion":2608,"completion":68,"start":2609,"enrollment":15,"conditions":2610,"interventions":2611},"NCT00075660","3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma",[40],"2005-10-04","2004-05-11",[196],[2596],{"trials":2613,"activeCount":8},[],{"trials":2615,"activeCount":8},[],{"trials":2617,"activeCount":8},[],{"intervention":323,"totalTrials":1388,"cells":2619},{"EARLY_PHASE1":2620,"PHASE1":2622,"PHASE2":2624,"PHASE3":2630,"PHASE4":2632,"NA":2634},{"trials":2621,"activeCount":8},[],{"trials":2623,"activeCount":8},[],{"trials":2625,"activeCount":8},[2626],{"nctId":315,"briefTitle":316,"status":55,"phases":2627,"primaryCompletion":318,"completion":204,"start":319,"enrollment":109,"conditions":2628,"interventions":2629},[39,40],[321],[323,75],{"trials":2631,"activeCount":8},[],{"trials":2633,"activeCount":8},[],{"trials":2635,"activeCount":8},[],{"intervention":244,"totalTrials":1388,"cells":2637},{"EARLY_PHASE1":2638,"PHASE1":2640,"PHASE2":2642,"PHASE3":2648,"PHASE4":2650,"NA":2652},{"trials":2639,"activeCount":8},[],{"trials":2641,"activeCount":8},[],{"trials":2643,"activeCount":8},[2644],{"nctId":235,"briefTitle":236,"status":55,"phases":2645,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":2646,"interventions":2647},[39,40],[14],[244,181,222],{"trials":2649,"activeCount":8},[],{"trials":2651,"activeCount":8},[],{"trials":2653,"activeCount":8},[],{"intervention":2655,"totalTrials":1388,"cells":2656},"sunitinib malate",{"EARLY_PHASE1":2657,"PHASE1":2659,"PHASE2":2661,"PHASE3":2671,"PHASE4":2673,"NA":2675},{"trials":2658,"activeCount":8},[],{"trials":2660,"activeCount":8},[],{"trials":2662,"activeCount":8},[2663],{"nctId":2664,"briefTitle":2665,"status":55,"phases":2666,"primaryCompletion":2667,"completion":259,"start":2668,"enrollment":602,"conditions":2669,"interventions":2670},"NCT00482755","Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery",[40],"2010-03-15","2009-04-08",[14],[2655],{"trials":2672,"activeCount":8},[],{"trials":2674,"activeCount":8},[],{"trials":2676,"activeCount":8},[],{"intervention":2678,"totalTrials":1388,"cells":2679},"PF-03446962",{"EARLY_PHASE1":2680,"PHASE1":2682,"PHASE2":2684,"PHASE3":2695,"PHASE4":2697,"NA":2699},{"trials":2681,"activeCount":8},[],{"trials":2683,"activeCount":8},[],{"trials":2685,"activeCount":8},[2686],{"nctId":2687,"briefTitle":2688,"status":55,"phases":2689,"primaryCompletion":2690,"completion":623,"start":2691,"enrollment":1269,"conditions":2692,"interventions":2694},"NCT01486368","A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma",[40],"2014-04-27","2012-06-26",[2693],"Malignant Pleural Mesothelioma",[2678],{"trials":2696,"activeCount":8},[],{"trials":2698,"activeCount":8},[],{"trials":2700,"activeCount":8},[],{"intervention":2702,"totalTrials":1388,"cells":2703},"AT9283",{"EARLY_PHASE1":2704,"PHASE1":2706,"PHASE2":2708,"PHASE3":2718,"PHASE4":2720,"NA":2722},{"trials":2705,"activeCount":8},[],{"trials":2707,"activeCount":8},[],{"trials":2709,"activeCount":8},[2710],{"nctId":2711,"briefTitle":2712,"status":55,"phases":2713,"primaryCompletion":2300,"completion":456,"start":2714,"enrollment":182,"conditions":2715,"interventions":2717},"NCT01145989","A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma",[40],"2011-02-15",[2716],"Multiple Myeloma",[2702],{"trials":2719,"activeCount":8},[],{"trials":2721,"activeCount":8},[],{"trials":2723,"activeCount":8},[],{"intervention":568,"totalTrials":1388,"cells":2725},{"EARLY_PHASE1":2726,"PHASE1":2728,"PHASE2":2730,"PHASE3":2736,"PHASE4":2738,"NA":2740},{"trials":2727,"activeCount":8},[],{"trials":2729,"activeCount":8},[],{"trials":2731,"activeCount":8},[2732],{"nctId":560,"briefTitle":561,"status":55,"phases":2733,"primaryCompletion":563,"completion":204,"start":564,"enrollment":565,"conditions":2734,"interventions":2735},[40],[25],[150,313,163,264,568],{"trials":2737,"activeCount":8},[],{"trials":2739,"activeCount":8},[],{"trials":2741,"activeCount":8},[],{"intervention":209,"totalTrials":1101,"cells":2743},{"EARLY_PHASE1":2744,"PHASE1":2746,"PHASE2":2756,"PHASE3":2758,"PHASE4":2760,"NA":2762},{"trials":2745,"activeCount":8},[],{"trials":2747,"activeCount":8},[2748,2752],{"nctId":200,"briefTitle":201,"status":55,"phases":2749,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":2750,"interventions":2751},[39],[20],[209,181,210,211],{"nctId":224,"briefTitle":225,"status":55,"phases":2753,"primaryCompletion":227,"completion":228,"start":229,"enrollment":11,"conditions":2754,"interventions":2755},[39],[20],[209,181],{"trials":2757,"activeCount":8},[],{"trials":2759,"activeCount":8},[],{"trials":2761,"activeCount":8},[],{"trials":2763,"activeCount":8},[],{"intervention":2765,"totalTrials":1388,"cells":2766},"MG 98",{"EARLY_PHASE1":2767,"PHASE1":2769,"PHASE2":2779,"PHASE3":2781,"PHASE4":2783,"NA":2785},{"trials":2768,"activeCount":8},[],{"trials":2770,"activeCount":8},[2771],{"nctId":2772,"briefTitle":2773,"status":55,"phases":2774,"primaryCompletion":2775,"completion":68,"start":2776,"enrollment":15,"conditions":2777,"interventions":2778},"NCT00003890","MG98 in Treating Patients With Advanced Solid Tumors",[39],"2001-09-27","1999-02-22",[20],[2765],{"trials":2780,"activeCount":8},[],{"trials":2782,"activeCount":8},[],{"trials":2784,"activeCount":8},[],{"trials":2786,"activeCount":8},[],{"intervention":210,"totalTrials":1388,"cells":2788},{"EARLY_PHASE1":2789,"PHASE1":2791,"PHASE2":2797,"PHASE3":2799,"PHASE4":2801,"NA":2803},{"trials":2790,"activeCount":8},[],{"trials":2792,"activeCount":8},[2793],{"nctId":200,"briefTitle":201,"status":55,"phases":2794,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":2795,"interventions":2796},[39],[20],[209,181,210,211],{"trials":2798,"activeCount":8},[],{"trials":2800,"activeCount":8},[],{"trials":2802,"activeCount":8},[],{"trials":2804,"activeCount":8},[],{"intervention":211,"totalTrials":1388,"cells":2806},{"EARLY_PHASE1":2807,"PHASE1":2809,"PHASE2":2815,"PHASE3":2817,"PHASE4":2819,"NA":2821},{"trials":2808,"activeCount":8},[],{"trials":2810,"activeCount":8},[2811],{"nctId":200,"briefTitle":201,"status":55,"phases":2812,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":2813,"interventions":2814},[39],[20],[209,181,210,211],{"trials":2816,"activeCount":8},[],{"trials":2818,"activeCount":8},[],{"trials":2820,"activeCount":8},[],{"trials":2822,"activeCount":8},[],{"intervention":2824,"totalTrials":1388,"cells":2825},"Imetelstat",{"EARLY_PHASE1":2826,"PHASE1":2828,"PHASE2":2840,"PHASE3":2842,"PHASE4":2844,"NA":2846},{"trials":2827,"activeCount":8},[],{"trials":2829,"activeCount":8},[2830],{"nctId":2831,"briefTitle":2832,"status":2833,"phases":2834,"primaryCompletion":2835,"completion":239,"start":2836,"enrollment":8,"conditions":2837,"interventions":2839},"NCT01916187","Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma","WITHDRAWN",[39],"2013-11-22","2013-07-30",[2838],"Neuroblastoma",[2824],{"trials":2841,"activeCount":8},[],{"trials":2843,"activeCount":8},[],{"trials":2845,"activeCount":8},[],{"trials":2847,"activeCount":8},[],{"intervention":2849,"totalTrials":1388,"cells":2850},"methadone hydrochloride",{"EARLY_PHASE1":2851,"PHASE1":2853,"PHASE2":2864,"PHASE3":2866,"PHASE4":2868,"NA":2870},{"trials":2852,"activeCount":8},[],{"trials":2854,"activeCount":8},[2855],{"nctId":2856,"briefTitle":2857,"status":270,"phases":2858,"primaryCompletion":204,"completion":204,"start":2859,"enrollment":182,"conditions":2860,"interventions":2863},"NCT00930332","Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain",[39],"2010-06-17",[2861,593,2862,20],"Nausea and Vomiting","Sleep Disorders",[2849],{"trials":2865,"activeCount":8},[],{"trials":2867,"activeCount":8},[],{"trials":2869,"activeCount":8},[],{"trials":2871,"activeCount":8},[],{"intervention":2873,"totalTrials":1388,"cells":2874},"CDKI AT7519",{"EARLY_PHASE1":2875,"PHASE1":2877,"PHASE2":2887,"PHASE3":2889,"PHASE4":2891,"NA":2893},{"trials":2876,"activeCount":8},[],{"trials":2878,"activeCount":8},[2879],{"nctId":2880,"briefTitle":2881,"status":55,"phases":2882,"primaryCompletion":2883,"completion":131,"start":2884,"enrollment":109,"conditions":2885,"interventions":2886},"NCT00390117","AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma",[39],"2012-03-13","2007-01-05",[25,20],[2873],{"trials":2888,"activeCount":8},[],{"trials":2890,"activeCount":8},[],{"trials":2892,"activeCount":8},[],{"trials":2894,"activeCount":8},[],{"intervention":77,"totalTrials":1388,"cells":2896},{"EARLY_PHASE1":2897,"PHASE1":2899,"PHASE2":2905,"PHASE3":2907,"PHASE4":2909,"NA":2911},{"trials":2898,"activeCount":8},[],{"trials":2900,"activeCount":8},[2901],{"nctId":64,"briefTitle":65,"status":55,"phases":2902,"primaryCompletion":67,"completion":68,"start":69,"enrollment":70,"conditions":2903,"interventions":2904},[39],[28,17],[73,46,74,75,76,77],{"trials":2906,"activeCount":8},[],{"trials":2908,"activeCount":8},[],{"trials":2910,"activeCount":8},[],{"trials":2912,"activeCount":8},[],{"intervention":2914,"totalTrials":1388,"cells":2915},"Aurora kinase inhibitor AT9283",{"EARLY_PHASE1":2916,"PHASE1":2918,"PHASE2":2929,"PHASE3":2931,"PHASE4":2933,"NA":2935},{"trials":2917,"activeCount":8},[],{"trials":2919,"activeCount":8},[2920],{"nctId":2921,"briefTitle":2922,"status":55,"phases":2923,"primaryCompletion":2924,"completion":204,"start":2925,"enrollment":2567,"conditions":2926,"interventions":2928},"NCT00443976","Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma",[39],"2010-04-09","2007-01-30",[2927,20],"Non-Hodgkins Lymphoma",[2914],{"trials":2930,"activeCount":8},[],{"trials":2932,"activeCount":8},[],{"trials":2934,"activeCount":8},[],{"trials":2936,"activeCount":8},[],{"intervention":2268,"totalTrials":1388,"cells":2938},{"EARLY_PHASE1":2939,"PHASE1":2941,"PHASE2":2947,"PHASE3":2949,"PHASE4":2951,"NA":2953},{"trials":2940,"activeCount":8},[],{"trials":2942,"activeCount":8},[2943],{"nctId":2261,"briefTitle":2262,"status":55,"phases":2944,"primaryCompletion":2264,"completion":204,"start":2265,"enrollment":2083,"conditions":2945,"interventions":2946},[39],[1271],[2254,2268,2269],{"trials":2948,"activeCount":8},[],{"trials":2950,"activeCount":8},[],{"trials":2952,"activeCount":8},[],{"trials":2954,"activeCount":8},[],{"intervention":2269,"totalTrials":1388,"cells":2956},{"EARLY_PHASE1":2957,"PHASE1":2959,"PHASE2":2965,"PHASE3":2967,"PHASE4":2969,"NA":2971},{"trials":2958,"activeCount":8},[],{"trials":2960,"activeCount":8},[2961],{"nctId":2261,"briefTitle":2262,"status":55,"phases":2962,"primaryCompletion":2264,"completion":204,"start":2265,"enrollment":2083,"conditions":2963,"interventions":2964},[39],[1271],[2254,2268,2269],{"trials":2966,"activeCount":8},[],{"trials":2968,"activeCount":8},[],{"trials":2970,"activeCount":8},[],{"trials":2972,"activeCount":8},[],{"intervention":2974,"totalTrials":1388,"cells":2975},"irinotecan hydrochloride",{"EARLY_PHASE1":2976,"PHASE1":2978,"PHASE2":2990,"PHASE3":2992,"PHASE4":2994,"NA":2996},{"trials":2977,"activeCount":8},[],{"trials":2979,"activeCount":8},[2980],{"nctId":2981,"briefTitle":2982,"status":55,"phases":2983,"primaryCompletion":2984,"completion":623,"start":2985,"enrollment":2986,"conditions":2987,"interventions":2988},"NCT00535353","AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer",[39],"2012-09-25","2008-01-02",26,[28],[2974,2989],"olaparib",{"trials":2991,"activeCount":8},[],{"trials":2993,"activeCount":8},[],{"trials":2995,"activeCount":8},[],{"trials":2997,"activeCount":8},[],{"intervention":2989,"totalTrials":1388,"cells":2999},{"EARLY_PHASE1":3000,"PHASE1":3002,"PHASE2":3008,"PHASE3":3010,"PHASE4":3012,"NA":3014},{"trials":3001,"activeCount":8},[],{"trials":3003,"activeCount":8},[3004],{"nctId":2981,"briefTitle":2982,"status":55,"phases":3005,"primaryCompletion":2984,"completion":623,"start":2985,"enrollment":2986,"conditions":3006,"interventions":3007},[39],[28],[2974,2989],{"trials":3009,"activeCount":8},[],{"trials":3011,"activeCount":8},[],{"trials":3013,"activeCount":8},[],{"trials":3015,"activeCount":8},[],{"intervention":1451,"totalTrials":852,"cells":3017},{"EARLY_PHASE1":3018,"PHASE1":3020,"PHASE2":3022,"PHASE3":3024,"PHASE4":3040,"NA":3042},{"trials":3019,"activeCount":8},[],{"trials":3021,"activeCount":8},[],{"trials":3023,"activeCount":8},[],{"trials":3025,"activeCount":8},[3026,3030],{"nctId":1443,"briefTitle":1444,"status":55,"phases":3027,"primaryCompletion":1446,"completion":204,"start":1447,"enrollment":1448,"conditions":3028,"interventions":3029},[41],[14],[1432,1451],{"nctId":3031,"briefTitle":3032,"status":55,"phases":3033,"primaryCompletion":3034,"completion":3035,"start":3036,"enrollment":3037,"conditions":3038,"interventions":3039},"NCT00083174","Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer",[41],"2011-03-25","2018-01-22","2004-12-03",4560,[14],[1451],{"trials":3041,"activeCount":8},[],{"trials":3043,"activeCount":8},[3044],{"nctId":3045,"briefTitle":3046,"status":55,"phases":3047,"primaryCompletion":943,"completion":85,"start":3048,"enrollment":3049,"conditions":3050,"interventions":3051},"NCT00066586","Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer",[43],"2001-08-01",98,[14],[1451]]